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ABSTRACT
BAYESIAN NONPARAMETRIC MODELS FOR CAUSAL INFERENCE AND CLUSTERING
UNDER DIRICHLET PROCESS PRIORS
Arman Oganisian
Jason A. Roy
Nandita Mitra
This body of work develops new Bayesian nonparametric (BNP) models for estimating causal effects with observational data. Though broadly applicable, it is motivated by statistical complexities
that frequently arise in health economics. Using potential outcomes, we formulate tailored causal
estimands and determine the conditions under which they are identifiable from observed data.
Once identified, flexible estimation follows from constructing models with high-dimensional sets of
parameters that are allowed to grow with the sample size. We employ the Dirichlet Process (DP),
and related stochastic processes, as priors over these high-dimensional spaces to do posterior
causal inference. First, motivated by complexities in medical cost distributions, we construct a generative two-part model for zero-inflated outcomes under a DP prior. This model is able to capture
structural zeros, skewness, and multimodality. We develop a Bayesian g-computation procedure
for causal estimation and use the induced partitioning of the DP to detect latent clusters of patients
with similar data distributions. Second, we extend this work to cost-effectiveness analyses, which
requires jointly modeling a bivariate outcome under right-censoring. Posterior causal inference is
done using a BNP joint model under the Enriched DP and Gamma Process priors. Finally, we
tackle the difficulties of estimating causal effects in multiple sparse subgroups. Using an improper
Hierarchical DP, we construct a new “hierarchical Bayesian bootstrap” prior that partially pools confounder information across subgroups when performing g-computation. This allows for potential
efficiency gains without imposing strong parametric assumptions on the confounder distributions.
A key contribution throughout is the construction of Markov Chain Monte Carlo (MCMC) algorithms
for efficient posterior sampling.
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CHAPTER 1
I NTRODUCTION
This dissertation develops new Bayesian nonparametric (BNP) models for estimating causal effects
with observational data. Bayesian approaches for causal inference date back to early work by
Rubin, 1978 who framed the task as a type of missing data problem in a finite sample. Specifically,
with a binary treatment we only observe one of two potential outcomes for each subject. From a
Bayesian perspective, each subject’s counterfactual is simply treated as an unknown/missing value
which can be drawn from its posterior distribution under certain assumptions. This posterior then
induces a posterior over functionals of the potential outcomes, such as sample average treatment
effects. This missing-data perspective has been reviewed recently by Ding and Li, 2018.
Over the last few decades, the desire for more robust estimation of population-level causal effects
has led to development of BNP methods. BNP models involve a high-dimensional set of parameters that is typically allowed to grow with the sample size - affording them a high degree of flexibility.
Special priors over these high-dimensional spaces are used to define a suitably regularized posterior over the model space. Many well-known models such as Bayesian additive regression trees
(Chipman, George, and McCulloch, 2010) and Gaussian processes (Rasmussen and Williams,
2005), for instance, belong to this class. An introduction and review of these methods in causal
inference is provided by Oganisian and Roy, 2021.
In our view, BNP methods add value over classical nonparametric/machine learning methods in
several ways. First, while most nonparametric methods from regression trees to kernel regression
involve regularization, it is often done through ad-hoc penalties on the objective functions. In BNP
methods, regularization is done in a more principled way via prior measures and uncertainty in
the regularization flows through to the posterior automatically. Second, as opposed to classical
machine learning methods where uncertainty estimation tends to be more complicated relative to
point-estimation, BNP methods can do both quite easily since the output is a full posterior distribution. Summarizing the center and dispersion of the posterior in a number of ways is relatively easy
once we have the posterior. Third, in causal inference targets of inference tend to be functionals
(often integrals) over relevant models. An appealing property of fully Bayesian inference is that a
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posterior over the model induces a posterior over these functionals and required integrals over the
model can be performed with relative ease via Monte Carlo.
Here, we will primarily be developing Dirichlet Process (DP) mixtures which, at a high level, are
BNP approaches that model outcome distributions as a data-adaptive mixtures of simpler distributions. At a low-level, the DP is a stochastic process that generates random discrete probability
distributions. Due to conjugacy and overall tractability, it has become a canonical nonparametric
prior over unknown probability distributions. It is a “nonparametric” prior in the sense that the distributions generated by the DP do not belong to any particular parametric family. DP mixtures follow
from placing a DP prior over the mixing distribution of a mixture model. Over the years, the DP
has been generalized and extended in several ways. For instance, the enriched DP (EDP) and
the hierarchical DP (HDP) have unique properties which are useful for addressing important causal
modeling challenges. Though broadly applicable to a wide range of applications, our BNP modeling
solutions are particularly motivated by challenges in health economics.
In Chapter 2, we develop a generative BNP model equipped to handle outcomes that exhibit structural zeros, multi-modalities, and skewed tails. Such outcomes are quite common in analyses of
medical costs in economics as some subjects may never accrue cost while others may accrue very
high costs. However, applications include ecology (modeling rainfall: there can be many days/areas
with no rain), actuarial sciences (modeling insurance payouts: some plans never paying out during a coverage period), and biomedical studies (modeling blood concentration of some biomarker:
concentrations below limit of detection will return zero). Our approach specifies a joint model for the
outcome, the propensity score, and the confounders with DP prior over the unknown distribution of
the subject-specific parameters governing this joint. The DP probabilistically partitions the complex
joint into more homogenous subregions/clusters and assigns each its own parameter vector. Importantly, the number of clusters that form is not pre-specified and is bounded only by the sample
size. Thus, this model is capable of capturing complexities that models with a single set of finitedimensional parameters cannot. We show how posterior output from this model can be (1) used
in a g-computation algorithm for computing causal effects, (2) conduct posterior predictive checks
around important causal assumptions, and (3) infer both soft and hard latent cluster assignments
for subjects who share similar joint data distributions. An Markov chain Monte Carlo (MCMC) algorithm for posterior inference via auxiliary variables is outlined and simulations assessing frequentist

2

properties are performed. We apply the model to analyze medical costs accrued by patients diagnosed with endometrial cancer and subsequently assigned to post-operative chemotherapy and
radiation therapy.
In Chapter 3 we extend the work of Chapter 2 to the setting of cost-effectiveness analyses (CEAs).
CEAs are employed in health policy and economics to evaluate whether the benefits associated
with a particular treatment outweigh the medical costs - with results often used to inform efficient
resource allocation and production. In cancer studies, the most common efficacy measure is increased in survival time. This makes CEAs statistically challenging as we must now deal with
modeling a bivariate outcome (cost and survival time) jointly under right-censoring. In this chapter
we first define causal contrasts in terms of expected potential monetary value accrued under each
treatment. We then define a causal net monetary benefit is the difference in the expected potential monetary value of two treatments and identify it under a set of causal assumptions. We then
construct a BNP model for cost-efficacy based on an enriched DP (EDP) and Gamma Process
priors and use it in a posterior g-computation procedure to obtain draws from the posterior of the
causal net monetary benefit estimand. Simulations are performed, posterior MCMC computation
is outlined, and the model is applied to a CEA of radiation versus chemotherapy for endometrial
cancer.
Finally, in Chapter 4, we tackle the important challenge of heterogenous treatment effect (HTE)
estimation. HTEs are causal effects within subpopulations defined by the strata of some variable
of interest (e.g. within education levels, income brackets, phenotypes, genotypes, etc.). The primary interest lies in how these causal effects vary (display “heterogeneity”) across strata. This often involves integrating stratum-specific outcome regressions over the stratum-specific confounder
distributions. While some Bayesian pooling can be done across strata when estimating the regression models, usually the confounder distributions are estimated flexibly - but independently via a Bayesian bootstrap (Rubin, 1981) or the empirical distribution. This, however, provides poor
performance when strata are too sparse to yield such flexible estimates of the confounder distributions. We formate a hierarchical Bayesian bootstrap (HBB) prior using hierarchical DPs. The
resulting posterior allows for borrowing of confounder information across strata, with more borrowing in sparse strata and less borrowing for populous strata. A conjugate MCMC update procedure
is outlined and simulations are performed to assess frequentist operating characteristics. We show
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that our approach limits to the empirical distribution and make connections to the smoothed Bootstrap. We apply the model to estimate the adverse event rates of proton versus photon therapy
across cancer type strata.
In Chapter 5, we end with a brief discussion of our work within the broader context of causal
inference and and BNP modeling. Namely, we discuss the role Bayesian nonparametrics occupies
between classical statistical procedures that emphasize uncertainty estimation and more modern
machine learning methods that emphasize flexible point estimation. We discuss a resurgence of
BNP models in the computer science literature under the name of “probabilistic machine learning”
and give a few reasons for optimism about the role of BNP methods in causal inference.
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CHAPTER 2
B AYESIAN

NONPARAMETRIC MODEL FOR ZERO - INFLATED OUTCOMES :

PREDICTION , CLUSTERING , AND CAUSAL INFERENCE

2.1. Overview and Motivation
Researchers across many fields are often interested in outcome prediction, clustering analysis, and
causal inference. For example, researchers in personalized medicine are broadly concerned with
forming out-of-sample outcome predictions given a subject’s covariates. Health economists are often interested in subgroup identification for resource allocation purposes and may turn to algorithms
such as K-means. Policy researchers, on the other hand, focus on causality - estimating the average difference in outcomes that would have occurred under hypothetical policy interventions. All
of these tasks become challenging in the presence of zero-inflated outcomes, multi-modality, and
extreme skewness. Structural zeros often need to be modeled: if causal treatment effect estimation
is the goal, failing to capture a difference in prevalence of zeros between treatment groups may
bias effect estimates. For prediction purposes, it is necessary to capture outcomes at the skewed
high-end of the distribution as well as predicting the structural zeros at the low-end. Failing to do so
would tarnish predictions at both tails. For clustering analyses, having to pre-specify the number of
clusters - typically an unknown quantity - poses a significant challenge.
In this paper, we develop a Bayesian nonparametric (BNP) generative model that simultaneously
predicts structural zeros as a function of covariates, captures skewness in both the outcome and
continuous covariates, and induces a grouping of subjects into clusters with similar joint data distributions. The result is a flexible, multi-purpose model that is broadly applicable to the tasks described above. We demonstrate the ability of our model to produce robust causal effect estimates
via standardization - a common method for computing marginal causal contrasts while adjusting
for measured confounders. This fully Bayesian approach allows uncertainty to propagate through
to the causal estimates, allowing point and interval estimation of various causal contrasts such as
mean differences and quantile causal effects. Moreover, posterior predictive checks around positivity - a key causal identification assumption - can be readily conducted using the model output.
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In particular, we propose a Dirichlet Process (DP) mixture of zero-inflated regressions. Each zeroinflated regression is a two-part model: a model for the probability of the outcome being zero and
a regression for the continuous, non-zero outcomes. DP mixtures (Ferguson, 1973) are a class
of BNP models that partition a complex joint distribution of the outcome and covariates into more
homogeneous clusters. In our case, the cluster-specific conditional means are modeled using
a zero-inflated regression. Unlike finite mixtures, DP mixtures assume there are infinitely many
clusters in the population - removing the need to specify the number of clusters in advance. As
many clusters are introduced as are needed to accommodate the complexity of the data. If the
data are not complex and can be adequately fit with a parametric model, new clusters form less
often. In this sense, our model is data adaptive - growing in proportion to the complexity of the data.
The flexibility and relative ease of constructing point and interval estimates for various types of contrasts are perhaps some of the reasons that BNP methods have been growing in popularity within
the causal inference literature. For example, Bayesian additive regression trees (BART) (Chipman,
George, and McCulloch, 2010; Hill, 2011) have been used to estimate causal treatment effects. Dependent Dirichlet process methods have been developed for estimating marginal structural models
(Roy, Lum, and Daniels, 2017) and dynamic treatment regime models (Xu et al., 2016). Dirichlet
process mixture approaches for mediation analysis (Kim et al., 2017) and Enriched Dirichlet process (Wade et al., 2014) mixture approaches to standardization have also been developed (Roy et
al., 2018). However, these methods do not address the complications of zero-inflation discussed.
We advance existing methodology by developing a BNP standardization approach that accounts
for zero-inflation.
Several factors distinguish our approach from the existing zero-inflated models outside of the causal
inference literature. As opposed to the parametric Bayesian approach of Ghosh, Mukhopadhyay,
and Lu, 2006, our method is non-parametric and, therefore, better suited for complex data. Barcella
et al., 2016 develop a DP mixture of poisson regressions. Though this provides a flexible fit to count
data, it is inappropriate for semi-continuous data. Linero, Sinha, and Lipsitz, 2018 develop a semiparametric Bayesian model for semi-continuous outcomes. They use a two-part model - a probit
model for the probability of a zero and a parametric density for non-zero outcomes. The mean functions of both models are jointly estimated using a BART-based model. In contrast, our model is fully
nonparametric, DP-based as opposed to BART-based, and generative as opposed to conditional.
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That is, our model estimates the full joint data distribution rather than solely a conditional outcome
distribution. The strength of DP-based procedures over BART-based procedures is that the former
induces clustering - allowing us to capture multi-modalities. Using generative models as opposed
to conditional models provides a framework for flexibly imputing missing data, as was demonstrated
by Roy et al., 2018.
Though broadly applicable, we motivate our approach throughout the paper by the analysis of medical cost outcomes - an important use case of our method. Zero-inflation is the norm in cost data
as patients may tend to have zero costs through mechanisms that depend on measured covariates
and the assigned treatment. Medical costs also tend to be skewed by especially high-cost patients.
Moreover, the joint distribution tends to be multi-modal with groups of patients that exhibit different cost-covariate relationships. Legislators and regulators often make use of economic analyses
comparing costs associated with proposed policy interventions. These comparisons are causal in
nature and require robust statistical modeling while adjusting for confounders.

2.2. Dirichlet Process Mixture of Zero-Inflated Regressions
2.2.1. A Generative Model
Consider observing data D = (Di )i=1:n = (Yi , Ai , Li )i=1:n from n independently sampled subjects.
The q × 1 covariate vector, Li , contains both categorical and continuous covariates measured pretreatment. The scalar Ai ∈ {0, 1} denotes binary treatment assignment. The scalar outcome is Yi whose empirical distribution may exhibit excess zeros, skewness, and multimodality. We first define
covariate vectors for subject i as xi = (1, Ai , Li )0 and mi = (1, Li )0 . We specify a generative model
- that is, a model for the full joint p(Di | ωi ) = p(Yi | Ai , Li , ωi )p(Ai | Li , ωi )p(Li | ωi ). Hierarchically
this is given by,

Yi | Ai , Li , βi , γi , φi ∼ π(x0i γi )δ0 (yi ) + 1 − π(x0i γi ) · N (yi | x0i βi , φi )


Ai | Li , ηi ∼ Ber expit(m0i ηi )
(2.1)

Li | θi ∼ p(li | θi )
ωi | G ∼ G
G | α, G0 ∼ DP (αG0 )
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Above, we define ωi = (βi , φi , γi , ηi , θi ) for compactness. The conditional distribution of the outcome, Yi , is modeled as a two-part mixture of a point-mass at 0, δ0 (yi ) = I(yi = 0), and a Gaussian
distribution with mean x0i βi and variance φi . This allows for a positive probability of the outcome being zero, P (Yi = 0) = π(x0i γi ) = expit(x0i γi ). This probability is modeled as a function of treatment
and confounders using a logistic regression with a (q + 2) × 1 parameter vector γi . Separately, the
conditional mean of non-zero outcomes is modeled using a regression with a (q + 2) × 1 parameter
vector βi . Though we use logit links to model π(x0i γi ) and P (Ai = 1 | Li , ηi ), other links, such as
the probit, could be used as well. In anticipation of subsequent application to causal estimation,
we model treatment probability (i.e., the propensity score) as a function of confounders, Li , using
a logistic regression with a (q + 1) × 1 parameter vector ηi . Finally, a joint distribution over the
confounders, p(li |θi ), is specified and governed by a vector of parameters θi . Since specification is
application-specific, we leave this distribution in general terms.
We assume subject-specific parameters are drawn from some distribution G. We place a DP prior
with base distribution G0 and concentration parameter α on G - denoted as G ∼ DP (αG0 ). The
DP is a “distribution over distributions” Ferguson, 1973 and draws from a DP are discrete - implying
a positive probability of ties among the subject-specific parameters. In other words, the DP prior
induces a clustering of patients who are more homogeneous in terms of the parameters that govern
the joint distribution of their data - including the conditional outcome distribution, structural zero distribution, propensity score distribution, and covariate distribution. The DP model allows the number
of clusters and, therefore, parameters to grow with the sample size - making this a nonparametric
model despite the seemingly rigid assumptions in Equation 2.1 (Hannah, Blei, and Powell, 2011).
The model is data-adaptive in the sense that more clusters are introduced to capture data complexities (e.g. non-linear and non-additive covariate effects, multimodalities, skewness, etc). However,
if the data are simple enough to be explained by a single cluster/set of parameters, then the model
shrinks to a parametric one with linear, additive covariate effects given in Equation 2.1 (with ωi
being equal to some common ω ∗ , ∀i).
This model has several desirable properties when it comes to complex data such as cost outcomes, which we use as the motivating example throughout the paper. The clustering accounts
for multi-modality in cost distributions. Structural zeros are modeled as a function of treatment
and confounders. For causal inference, this model admits a flexible predictive distribution which,
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as we will see, can be incorporated into a standardization procedure. Finally, explicit modeling of
treatment assignment allows us to conduct posterior predictive checks assessing the validity of the
positivity assumption. We note that in application areas where outcomes are non-negative and observed data are close to zero, a local Gaussian distribution that ignores the non-negative nature of
the outcome is undesirable. In these instances, we can proceed with the model as presented after
log-transforming non-zero values - essentially assuming a log-Normal distribution for these values.
Appendix A.6 provides more details along with a proof-of-concept simulation.
2.2.2. Posterior Sampling and Hyperparameters
Using the Pólya Urn (Blackwell and MacQueen, 1973) representation of the DP, it can be shown
that the conditional posterior of ωi is given by (Muller et al., 2015),

p(ωi |ω1:(i−1) , D) ∝

h
i
X
1
αp(Di |ωi )G0 (ωi ) +
p(Di |ωj )δωj (ωi )
α+i−1
j<i

(2.2)

where Di = (Yi , Ai , Li ) is the data vector for the ith subject. The posterior clustering of patients is evident in Equation 2.2. Subject i’s parameter, ωi , can equal one of the previously
drawn parameters, ωj , with probability proportional to the subject’s likelihood evaluation under ωj ,
P
j<i p(Di |ωj ) · δωj (ωi ). Or, with probability proportional to αp(Di |ωi ), ωi can be a new, previously
unseen parameter drawn from the prior G0 (ωi ).
If subject i is quite unique so that its likelihood evaluation is low under the i − 1 existing parameters,
then it is relatively more likely for this subject to be assigned its own set of parameters from the
prior. Finally, note that as n gets large and i approaches n, the prior probability α/(α + i − 1) of the
ith subject being assigned to a new cluster goes to zero. This property helps prevent overfitting.
The conditional posterior in Equation 2.2 forms the basis of a Metropolis-in-Gibbs sampler we use
Qn
to sample ω1:n from the full posterior, p(ω1:n |D) = p(ω1 |D) i=2 p(ωi |ω1:(i−1) , D). The sampler
proceeds in the spirit of Neal’s Algorithm 8 (Neal, 2000) by introducing latent cluster membership
indicators, c1:n = (c1 , c2 , . . . , cn )0 , for the subjects. We initialize the algorithm by partitioning subjects
to one of K initial clusters. Each iteration t, with K (t) occupied clusters indexed by k, has two
(t)

steps. First, conditional on c1:n , we draw from the posterior of each model parameter based on
(t)

the likelihood contributions of all subjects with ci
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= k. Conditional on these updated parameter,

(t+1)

ω1:n , we update each assignment indicator
(t+1)

ci

(t)

|c1:(i−1) ∼ Cat




1
α
1
(t+1)
(t+1)
(t+1)
p(Di |ω1
p(Di |ωi−1 ),
p(Di |ω0
), . . . ,
)
α+i−1
α+i−1
α+i−1
(t+1)

Above, Cat(·) denotes the categorical distribution and ω0

each iteration. Notice that in each iteration subject i has a

∼ G0 is a draw from the prior taken at
(t+1)
α
)
α+i−1 p(Di |ω0

probability of being

assigned to a new cluster.
The two hyperparameters of the model in Equation 2.1 are the choice of base distribution, G0 , and
the concentration parameters α. A requirement for the base distribution is that it be over the space
of the parameters ωi = (βi , φi , γi , ηi , θi ). Prior independence is often assumed so that G0 can be
constructed as the product over parameter-specific priors. Conjugate priors for each parameter
may be used, if possible, to simplify MCMC computation. The concentration parameter α governs
how frequently new clusters appear in an MCMC run. It is often described as a prior sample size
for a new cluster. Following previous analyses (Roy et al., 2018), we place a α ∼ Gamma(1, 1)
prior on α rather than set it at a particular value. Examples of specifying G0 is given in Appendices
A.4, A.5, and A.6 for simulations, data analysis, and log-transform extension respectively.
2.2.3. Posterior Mode Clustering in the Presence of Label Switching
Often we may like to cluster patients using the posterior mode - allowing us to identify and summarize distinct groups in terms of observed characteristics. In mixture models, posterior mode
inference on cluster assignment is complicated by label switching (Rodrguez and Walker, 2014) the fact that cluster labels c1:n do not have consistent meanings across Gibbs iterations. For example, at iteration t, a new cluster, labeled cluster 2, may be proposed and all subjects previously in,
say, cluster 1 may be re-assigned to this new cluster. Even though the cluster label has changed
from 1 to 2, the cluster still contains the same subjects. Therefore, naively using the mode of the T
(1)

(T )

cluster indicators, ci , . . . , ci , as each subject as the mode assignment is problematic. To meaningfully cluster subjects based on posterior mode, we perform a deterministic relabeling of cluster
indicators after posterior sampling (Dahl, 2006; Stephens, 2000). We compute for each iteration t
an n × n adjacency matrix with a one in the (i, j)th entry indicating patients i and j were clustered
together and zero indicating otherwise. The element-wise mean of this matrix across the t iterations gives us a posterior mode matrix with (i, j)th entry being the posterior probability of patients i
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and j being clustered together. To obtain cluster assignments, we select the adjacency matrix that
is closest in the L2 sense to the posterior mode matrix. More details regarding the relabeling is
provided in Appendix A.2.

2.3. Counterfactual Prediction and Estimating Causal Contrasts
2.3.1. Review of Counterfactuals and Causal Estimation
We first provide a motivating review of causal estimation before discussing our BNP standardization procedure. Consider observing D = (Yi , Ai , Li )i=1:n as defined in Section 2.2.1 from some
target population we wish to make inference about. Using potential outcome notation, let the random variable Y A=a represent the potential outcome under treatment A = a. The marginal causal
h
i
effect of treatment on the outcome, Ψ = E Y A=1 − Y A=0 , can be computed via the method of
standardization under the standard causal identification assumptions (Rubin, 1978) of ignorability,
consistency, no interference, and positivity. Briefly, and in order, these assumptions require that all
confounders are controlled for, that there is only one form of each treatment, that each patient’s
outcome is independent of others’ treatment assignments, and that treatment assignment is not
deterministic for any individual in the population. We provide a formal statement in Appendix A.3.
In the Bayesian framework, standardization is conducted using the posterior predictive distribution
of the outcome (Keil et al., 2017). Throughout, we use tildes to denote posterior predictive draws.
Let Ỹ a denote the posterior predictive outcome under intervention A = a with predictive distribution
p(Ỹ a |D). Also, let L̃ denote a posterior predictive draw of confounders. If the causal assumptions
hold, standardization under intervention A = a is given by

E(Ỹ a |D) =

Z Z Z
E(Ỹ |A = a, L̃, β)p(L̃|θ)p(β, θ|D) dL̃ dβ dθ
θ

β

(2.3)

L̃

Above, β and θ are parameter vectors that govern the conditional distribution of the outcome
and the distribution of the confounders, respectively. This slightly differs from frequentist standardization by additionally averaging a prediction model for the outcome, E(Ỹ | A = a, L̃, β) ,
over the posterior distribution of the parameters, p(β, θ|D). Given T draws from the posterior
(θ(t) , β (t) )t=1:T , we can compute Equation 2.3 by first drawing ˜l(t) ∼ p(L̃|θ(t) ), then computing
E[Ỹ |A = a, L̃ = ˜l(t) , β (t) ]. This yields a posterior distribution for the difference {δ (t) }1:T = {E[Ỹ |A =
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1, L̃ = ˜l(t) , β (t) ] − E[Ỹ |A = 0, L̃ = ˜l(t) , β (t) ]}1:T . The posterior mean Ψ̂ = T −1

P

t

δ (t) can be taken

as a point estimate of Ψ, while percentiles can be used for interval estimation. Standardization in
Equation 2.3 crucially requires both a correctly specified regression for the outcome as well as an
accurate estimate of the marginal confounder distribution. As correct specification is unlikely, robust estimation requires nonparametric modeling. This is especially the case in medical cost data where multimodality, zero-inflation, and skewness are unlikely to be captured by simple parametric
models.
2.3.2. Sampling from the Posterior Predictive Distribution
The model outlined in Equation 2.1 yields a flexible predictive distribution, which in turn yields robust
causal effect estimates. Under standard causal identification assumptions, the posterior predictive
distribution of potential outcome Ỹ a is given by
p(Ỹ a |D) =

α
α+n

Z Z
p(Ỹ |A = a, L̃, ω̃)dP (L̃|ω̃)dG0 (ω̃)
ω̃

L̃

1
+
α+n

n
hZ X

Z
ω1:n

i
p(Ỹ |A = a, L̃, ωi )dP (L̃|ωi ) dP (ω1:n |D)

(2.4)

L̃ i=1

A derivation is provided in Appendix A.1. Note that the particular forms of p(Ỹ |A, L̃, ω) and p(L̃|ω)
are specified in Equation 2.1. We can draw from this distribution via Monte Carlo. For each of the
(t)

(t)

T posterior draws, (ω1:n )t=1:T from p(ω1:n |D), draw from the conditional distribution l ∼ p(L̃|ωi ).
(t)

(t)

Then, under intervention A = a, we can draw from ỹa ∼ p(Ỹ |A = a, L̃ = l, ωi ). For the tth draw,
the inner integral over ω̃ in Equation 2.4 can be evaluated numerically by drawing from the prior
ω̃0 ∼ G0 , then drawing confounders conditional on this prior draw ˜l ∼ p(˜l|ω̃0 ). This procedure yields
(t)

predictive draws {ỹa }t=1:T .
(t)

(t)

After obtaining draws {ỹ1 }1:T and {ỹ0 }1:T , we can compute T draws of the difference {δt }t=1:T ,
(t)

(t)

where δt = ỹ1 − y0 . Thus, a Bayesian nonparametric point estimate of Ψ is given by Ψ̂BN P =
P
E[Ỹ 1 |D] − E[Ỹ 0 |D] ≈ T1 t δt . Intervals can be constructed using percentiles of {δt }1:T . Quantile
causal effects and counterfactuals (Xu, Daniels, and Winterstein, 2018) may also be computed from
Equation 2.4. We estimate the posterior predictive CDF of the potential outcome under intervention
PT
(t)
a using the posterior predictive draws, Fa (v) = P (Y a ≤ v|D) ≈ T1 t=1 I(ỹa ≤ v). The inverse of
this estimated CDF can be used to estimate quantile causal effects. For instance, the median causal
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effect can be estimated as the difference in median cost under two interventions F1−1 (.5) − F0−1 (.5).
This contrast may be preferable to Ψ for skewed outcomes.
2.3.3. Assessing the Positivity Assumption
Positivity is the only identification assumptions that can be assessed empirically. The assumption
requires that the probability of treatment is bounded 0 < P (A = 1|L) < 1, ∀L. Violations of
positivity (e.g. P (A = 1|L) = 1) imply that there are subgroups of the data for which no comparator
patients exist, thus forcing the model to extrapolate when computing causal contrasts. Incorrect
extrapolation in these regions will bias causal effect estimates. There are many methods of handling
violations once they are identified (Petersen et al., 2012), but these are out of scope for this paper.
Here we simply provide a framework for assessing this assumption within the unique context of
our zero-infalted DP model. Note in Equation 2.1, we have explicitly modeled treatment probability
as a function of covariates. This allows us to predict treatment probability for each patient, given
t
posterior draws (ω1:n
)t=1:T via Monte Carlo:
T
1X
P (Ã = 1|l, D) ≈
T t=1

α
α+n

R
ω̃

Pn
(t)
(t)
1
p(Ã|l, ω̃)p(l|ω̃)dG0 (ω̃) + α+n
i=1 p(Ã|l, ωi )p(l|ωi )
R
Pn
(t)
α
1
i=1 p(l|ωi )
α+n ω̃ p(l|ω̃)dG0 (ω̃) + α+n

(2.5)

A derivation is provided in Appendix A.1. Using the above, we can compute P (Ãi = 1 | Li , D) for
each subject in our sample. Typically, histograms of these probabilities are plotted for treated and
untreated patients separately. Separated distributions indicate a lack of overlap and, therefore, high
posterior belief of a positivity violation.

2.4. Simulation Study
In this section, we evaluate bias of Ψ̂BN P , coverage of the credible interval estimates, and precision
of the estimate as measured by interval width. We compare results to existing methods that may
be considered by researchers faced with zero-inflated outcomes - namely BART, a non-Bayesian
doubly robust estimator, and two parametric Bayesian Gamma models. BART is a Bayesian nonparametric, tree-based ensemble for the conditional mean of the outcome. The doubly robust estimator is a two-part model for treatment assignment and the outcome. We use a boosted frequentist
logistic regression for the treatment model and a frequentist Gaussian model for the outcome. The
first parametric model is a Bayesian Gamma hurdle model. This is a two-part model that explicitly
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models the probability of the outcome being zero with a logistic regression, while modeling positive outcomes with a Gamma regression. The second parametric model is a naive, yet somewhat
common, approach of adding .01 to zero outcome values and modeling this transformed outcome
using a Bayesian Gamma regression. We refer to this as the Gamma +.01 model.
We simulate from two data generating processes (DGPs). In the clustered DGP, we simulate data
from three distinct clusters - each with its own set of parameters that govern confounder distributions, binary treatment assignment, zero-inflation, and Gamma-distributed positive outcomes. The
Gamma distribution is used to simulate realistic cost data that are non-negative and skewed within
each cluster. Thus, the local conditional outcome distribution assumed in Equation 2.1 is deliberately misspecified. In the parametric DGP, we simulate data from a single cluster with a common
covariate distribution, treatment assignment model, zero-inflation, and Gamma-distributed positive
outcomes. The data are skewed, but not multimodal. Other simulation details regarding hyperparameter settings and sampling are given in Appendix A.4.
Table 2.1: Results across 1000 simulated datasets with 3000 subjects each. Average bias of the
posterior mean is reported as a proportion of the true value (Ψ = −9740.3 in the clustered setting
and Ψ = −10184.1 in the parametric setting). Mean credible interval widths are presented for the
Zero-inflated DP model, the BART model, and two Gamma models. Confidence intervals are given
for the doubly robust method. In the parametric setting, we have 45% in the clustered setting
and 55% in the parametric setting. We simulate with one continuous covariate and four binary
covariates, all of which affect zero-inflation, treatment probability, and the outcome. All models
condition on the simulated confounders so that ignorability holds.
DGP

Clustered

Parametric

Model
Zero-Inflated DP
BART
Doubly Robust
Gamma Hurdle
Gamma +.01
Zero-Inflated DP
BART
Doubly Robust
Gamma Hurdle
Gamma +.01

Bias
-.081
-.746
.795
-.509
1.817
.097
-.054
-.027
-.014
-.489

Coverage
94.3%
76.2%
87.1%
79.8%
4.7%
95.1%
96.1%
95.9%
95.1%
100%

Interval Width
21612.2
26374.2
33449.3
19692.2
27358.1
22034.1
23825.3
23339.1
21778.7
50580.3

In the clustered setting, the zero-inflated DP model produces effect estimates with the smallest
bias - −8.1% of the true value. The 95% credible interval has close to nominal coverage of 94.2%.
Though the Gamma hurdle model cannot handle multimodality, it outperforms both BART and the
doubly robust estimators due to its explicit modeling of structural zeros and skewness. The latter
two models capture neither zero-inflation nor multimodality and consequently perform poorly.
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In the parametric setting, the zero-inflated DP model again exhibits low bias and close to nominal
coverage. BART and the doubly robust models have lower bias, but exhibit slight overcoverage
(about 96%) in the interval estimates. The Gamma hurdle model is correctly specified in the parametric DGP and so performs the best - exhibiting the lowest bias of 1.4%, 95.1% coverage, and
yielding the shortest interval. Relative to this correctly specified hurdle model, the Zero-inflated
DP has only a slightly wider interval length on average (22034.1 versus 21778.7), suggesting little
efficiency loss. BART and the doubly robust estimators both have wider intervals than the DP on
average.
The particularly bad performance of the naive Gamma +.01 model - under both DGPs - should be
noted. While it is a simple, seemingly harmless trick, adding a small constant severely degrades the
accuracy and precision of treatment effect estimates. Unlike the hurdle model and DP model, it does
not model structural zeros, and so ignores the effect of treatment that generates these zeros. The
zero-inflated DP mixture captures multi-modality, skewness, and the treatment’s effect on structural
zeros. This allows for good treatment effect estimates under both simple and pathological data
distributions with minimal efficiency loss if the parametric model is correct.

2.5. Application: Inpatient Medical Costs of Endometrial Cancer Treatments
In this section, we use the proposed DP mixture of zero-inflated regressions to analyze inpatient
medical costs among patients with endometrial cancer. Patients who were diagnosed with endometrial cancer between 2000 and 2014 were identified in the SEER Medicare database. Those
assigned to either radiation or chemotherapy post-hysterectomy were followed for a maximum of
two years after initial treatment. The total inpatient costs, measured in 2018 US dollars, accrued
over the followup period was recorded and is our primary outcome of interest. Inpatient costs are
costs that accrue during overnight hospitalizations and do not include costs such as prescription
treatment costs, outpatient costs, or hospice care costs.
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Table 2.2: Baseline Characteristics: Means and standard deviations are reported for continuous
variables. Counts and percentages are reported for categorical variables. Standardized mean
differences (SMD) are provided. All monetary amounts are in thousands of 2018 U.S. Dollars.
Chemotherapy

Radiation

(N=92)

(N=952)

Total Inpatient Costs ($)

22.1 (28.6)

23.4 (34.5)

Zero Costs

14 (15.2%)

75 (7.9%)

Age (years)

73.68 (6.98)

73.25 (5.98)

.066

Household Income ($)

64.4 (32.4)

56.8 (26.2)

.257

White

76 (82.6%)

835 (87.8%)

.147

Diabetic

20 (21.7%)

197 (20.7%)

.026

CCI

SMD

.039

.350

0

49 (53.3%)

529 (55.6%)

1

22 (23.9%)

260 (27.3%)

≥2

21 (22.8%)

131 ( 13.8%)

Grade = 1

28 (30.4%)

208 (21.8%)

.196

FIGO Stage I-N0 or I-A

63 (68.5%)

357 (37.5%)

.653

Table 2.2 presents baseline characteristics of the two treatment groups. There is a significant
proportion of zero costs - 15.2% in the chemotherapy arm versus 7.9% in the radiation arm.
Chemotherapy subjects have lower inpatient costs over the follow up period. However, there may
be several confounding factors. For example, the primary determinants of post-hysterectomy treatment are the stage and grade of the cancer, with consideration for patient commorbidity and age.
These factors, which are measured pre-treatment, likely also affect inpatient costs. The standardized mean difference for stage, grade, and CCI are all > .1.
In the following subsections, we demonstrate how our method can be used to model the data from
several angles. All results are from posterior sampling of the model in Equation 2.1. We control
for race, CCI, household income, cancer grade and stage in both the positive outcome model and
the zero-probability model. We model treatment assignment as a function of these confounders
as well. We assume local Gaussian distributions for CCI and household income and Bernoulli
distributions for binary covariates. Details about hyperparameter settings, priors, and sampling
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results are provided in Appendix A.5.
2.5.1. Multi-modality and Clustering Results
The patients in this study are heterogeneous in terms of their observed costs and covariates.
Some have extremely high costs, more comorbidities, and come from varying socio-economic backgrounds. Clustering can be useful for both describing these groups in terms of observed characteristics or motivating new research. There is a vast literature on clustering methods and we do not
claim the DP-induced method is superior, but it does have several advantages. First, since the DP
mixture assumes there are infinitely many clusters in the population (though in a particular analysis,
the number of clusters is bounded by n), we need not specify the number of clusters beforehand.
Second, this method allows for uncertainty quantification around the posterior mode data partition.

Figure 2.1: Clustering results from the zero-inflated DP mixture. Colors indicate posterior mode cluster
assignment. The first panel projects clustering results onto the cost-income space and the second projects the
results onto the cost-CCI space - both relevant dimensions for understanding costs. The third panel visualizes
the full posterior mode matrix discussed in Section 2.2.3 with a network diagram. Each node represents
a patient and the lengths of vertices connecting any two nodes are inversely proportional to the posterior
probability of being clustered together. The position of the nodes in x-y space have no meaning (hence the
absence of axis labels), only the relative distance between nodes are relevant.

Two potentially important confounders of costs and treatment assignment are household income
and CCI. The first two panels of Figure 2.1 visualize cost along these dimensions. While we initialize
the model with five clusters, the model identified ten clusters in the posterior - introducing five
additional clusters to accommodate the complexity of the data. In the first panel, we see the orange
cluster has very high costs, the blue cluster has moderately high costs, while the green and red
clusters have lower costs. There are two results worth noting. First, the light blue and gray clusters
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represent patients who have such distinctly high costs that the DP model places them in their own
cluster. Second, the black points represent patients who, while having similar costs to most patients,
have distinctly high household income. Thus the DP model places them in their own cluster. From
this we can see that the clustering is happening in multiple dimensions rather than only on the cost
space.
Similarly, we cannot see much difference between the green and red clusters on the cost-household
income space. However, the second panel shows that these patients occupy distinct places on the
cost-CCI space, where the red cluster ranks lower than green on CCI. It may be clear at this point
that visualizing clustering in two-dimensions is limited by the need to choose the variables on each
dimension. The third panel solves this issue by visualizing the entire posterior mode matrix discussed in Section 2.2.3 as a network diagram. We can use this diagram to get a sense of the
uncertainty around the mode cluster assignment/partition. For example, the nodes between the
red and green cluster have very uncertain assignment. About half the time, they were clustered
with the red patients and the other half they were clustered with the green patients - indicating we
should not have very high confidence in their posterior mode assignment. This type of uncertainty
characterization is absent in many classical clustering algorithms, like K-means. We can summarize observed characteristics of patients by posterior mode assignment. In the orange cluster,
average cost in this cluster is $71,139. The distribution of CCI in this group is skewed much higher,
suggesting a possible positive association between cost and CCI. On the other hand, we can see
from Figure 1 that the light blue cluster has much higher costs (first panel), yet these subjects are
relatively low on the CCI scale (second panel). The relationship between cost and CCI seems
unclear - and perhaps this motivates future research targeted at learning this relationship.
2.5.2. Cost Prediction in Presence of Zero-Inflation
Induced clustering is the core strength of DP mixtures: a single parametric model estimated using
heterogeneous data will have worse fit than an ensemble of locally parametric models fit on more
homogeneous partitions. Figure 2.2 demonstrates the proposed model’s effectiveness at capturing
the cost distribution. The predictive cost distributions are quite similar to the observed distribution.
This is not the case for the BART and hurdle models - which fail to capture the high end of the
distribution and, therefore, consistently under-predict costs.
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Figure 2.2: Top row: QQ plots of percentiles (.02 - .98 in increments of .02) of the observed cost distribution
against predictive cost distributions. Each gray line is a draw of the same size as the data from the predictive
cost distribution. The blue line indicates the mean of each percentile across these predictive draws while the
dashed line indicates equality (a perfect fit). The DP mixture opens new cluster to capture skewness - resulting
in a predictive distribution closely matching the observed data. The BART model and hurdle model cannot
capture this extreme skewness. This is also demonstrated in the bottom row: the DP model occasionally
predicts very high costs, while predictions from BART and hurdle models hardly ever predict such high costs.

In the second row of plots, we see the DP model occasionally predicts very high costs, while having
the bulk of the predictions at < $50, 000. Both BART and the Hurdle model capture the lower end of
the cost distribution well - also predicting the bulk of the costs at < $50, 000. However, they rarely
predict costs at the high end - thus, failing to capture skewness.
2.5.3. Estimating Causal Contrasts and Assessing Overlap
Finally, we use our method to estimate differences in costs that would have accumulated over two
years under hypothetical interventions where everyone received radiation versus everyone received
chemotherapy as their first post-hysterectomy treatment. After applying the method of Section
2.3.3, Figure 2.3 shows there is adequate overlap between the two treatment groups, reducing
concerns about positivity violations.
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Figure 2.3: Posterior propensity scores calculated using Equation 2.5 for both groups indicate adequate
overlap - suggesting no evidence of positivity violations.

We use the method of Section 2.3 to compute a marginal causal effect, a median causal effect,
and a risk ratio contrasting the probability of zero cost under radiation versus chemotherapy. Posterior means and credible intervals are displayed in Table 4. Under standard causal identification
assumptions, we estimate the causal difference in costs to be $1672 (CI: −2566, 5722), showing
radiation therapy to be more expensive. We estimate a median causal difference to be $872 (CI:
−833, 2790). Finally, we estimate that the probability of having zero costs under radiation therapy is
50% (CI: 0.31, 0.78) lower than under chemotherapy. These results are consistent with unadjusted
results (see Table 2.2).
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Table 2.3: Posterior means and credible interval from standardization procedure using DP mixture
along with posterior marginal causal effect estimates and credible intervals from BART, a Gamma
hurdle model, and a Gamma model with zeros replaced by .01. All monetary amounts are in
thousands of 2018 U.S. Dollars.

Zero-Inflated DP

BART

Gamma Hurdle

Gamma +.01

Marginal Causal Effect

Median Causal Effect

Causal Risk Ratio of Zero Cost

1.7

.9

0.498

(-2.6, 5.7)

(-.8, 2.8)

(0.31, 0.78)

1.8

-

-

(-6.1, 9.8 )

-

-

2

-

.505

(-1.5, 5.6)

-

(.34, .76)

4.9

-

-

(1, 8.8)

marginal causal effects from BART and the Gamma hurdle model are roughly in-line with the DP
mixture estimates but suffer from relative ineffectiveness at predicting high costs, as explained in
the previous section. The risk ratio estimate from the hurdle model is similar to the DP estimate. We
note that, consistent with simulation results, the marginal causal effect estimate from the Gamma
+.01 model differs greatly from the other three models.

2.6. Discussion and Future work
The proposed DP mixture is ideal for capturing joint distributions with continuous, zero-inflated outcomes. It is multipurpose: simultaneously modeling structural zeros, inducing clustering to handle
multi-modality, and accommodating skewness in the outcome and covariates. As we show in our
simulation studies, these traits allow our proposed DP mixture to both produce high-quality causal
effects estimates as well as capture the entire outcome distribution. At the same time, posterior
draws from the model can be used to perform posterior checks evaluating the validity of positivity.
One might expect BART to perform better than it did in our simulations and in our analysis of cancer
data. After all, BART is said to be “effectively nonparametric” (Chipman, George, and McCulloch,
2010). However, while it flexibly models the conditional outcome mean, BART still assumes that
the outcome distribution is Gaussian - yielding biased estimates in simulation settings where the
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data are drawn from a skewed distribution like the Gamma. Moreover, it does not account for
multi-modality as it assumes the data are generated from a single mean function and single error
variance. The DP mixture makes no such assumptions - yielding better estimation of the entire
outcome distribution, as was shown in Figure 2.2. We note that very recently George et al., 2018
proposed extending BART by modeling the error term nonparametrically using a DP mixture. This
may better equip BART to handle skewness, though multi-modality will likely remain challenging.
Finally, we consider several extensions of our model for future work. First, while our model provides
a framework for assessing positivity, designing a solution within the framework of our model is
an important extension. Second, unmeasured confounding is always a concern in observational
studies. In our application this concern is mitigated by the fact that post-hysterectomy treatment
assignment mechanism is well defined by American Cancer Society guidelines to be mostly driven
by patient comorbidity, age, cancer stage, and grade. In many settings, the treatment mechanism
may be less well-understood, necessitating sensitivity analyses. Third, standardization provides
valid causal estimates only in scenarios with time-constant treatment and confounding. Extending
this model to a setting with time-varying confounding would be a worthwhile endeavor.

22

CHAPTER 3
B AYESIAN

NONPARAMETRIC COST- EFFECTIVENESS ANALYSES VIA

E NRICHED

D IRICHLET P ROCESS P RIOR
3.1. Introduction
Cost-effectiveness analyses (CEAs) are ubiquitous in public health policy and health economics
research, with use-cases ranging from treatment comparison to determining drug coverage and
informing policy. However, they remain statistically challenging for several reasons. First, cost and
effectiveness are often correlated, with joint distributions typically exhibiting extreme skewness and
multimodality. In these settings, parametric models that impose strong distributional, linearity, and
additivity assumptions are not tenable. Second, in many cases effectiveness is operationalized as
gains in survival time - which is prone to right-censoring if subjects drop out before the end of the
study. For such patients, we only observe a lower bound on their survival time and accumulated
costs. Third, CEAs are often conducted using observational data which are less expensive and
more readily available, but are prone to confounding. Valid estimation of CEA contrasts therefore
requires adjustment so that differences in cost-effectiveness due to treatment can be disentangled
from differences due to confounders.
Early statistical literature (Bang and Tsiatis, 2000; Lin, 2003; Lin, 2000; Lin et al., 1997) focused
on cost estimation, while assuming efficacy was constant between treatments. Cost estimation
alone is challenging due to the pathological nature of costs (censoring, skewness, zero-inflation,
etc). Our work enhances this literature by developing a joint model for cost and survival time, rather
than solely focusing on cost. Previous work decomposed the joint distribution into a product of a
marginal survival time distribution and a cost distribution conditional on survival time. Huang, 2002
refer to this as a “calibration regression” approach. Handorf et al., 2019 and Huang, 2002 approach
the modeling from a frequentist point of view. While the former uses a fully parametric approach, the
latter uses a semi-parametric approach - making only first and second moment assumptions. Baio,
2014 took a fully parametric Bayesian approach to joint modeling that did not allow for full covariate
adjustment since the data application of interest was from a randomized trial. In contrast, our
Bayesian joint modeling approach makes neither strong distributional assumptions nor functional
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form (e.g., linearity, additivity) assumptions and allows for covariate adjustment.
Li et al., 2018 took a significant step toward robust causal inference in cost-effectiveness. They formulate causal CEA contrasts in terms of potential outcomes and develop a doubly-robust estimation
approach that combines separate conditional mean models for cost and survival with a treatment
propensity score model. They show that CEA contrasts can be estimated consistently if either the
propensity score or cost/survival regressions are correct. We build on this work in several ways. We
also formulate CEA contrasts in terms of potential outcomes - endowing these contrasts with explicitly causal interpretations. However, our modeling approach is fully nonparametric and, therefore,
more flexible than the doubly-robust estimator. While, the doubly-robust approach only uses data
on uncensored subjects (weighted by the inverse probability of being uncensored) our approach
uses data from both censored and uncensored subjects potentially generating efficiency gains.
Moreover, our approach is a Bayesian model for the full joint cost-effectiveness distribution - not
a weighted combination of separate conditional mean models. This in principle allows for full posterior inference for any function of the joint distribution. Finally, our approach allows for covariatedependent censoring. Though Li et al., 2018 mention an extension to covariate-dependent censoring, the method proposed and analyzed in their paper relies on randomly censored survival
times.
Specifically, our proposed method decomposes the full joint cost-effectiveness distribution into a
survival distribution, and a cost model conditional on time. We specify a “local” parametric cost
model and a proportional hazard survival model. A Gamma process (GP) prior is placed on the
baseline hazard of the survival time distribution while an enriched Dirichlet process (EDP) prior
is placed on the cost and survival covariate effects of the local models, jointly. A key property
of the EDP is its induced posterior clustering. The EDP probabilistically partitions the dataset
into clusters with similar cost-effectiveness covariate effects and associates different “local” models
with each cluster. Thus, the joint posterior model for cost-effectiveness is an adaptive mixture
of locally parametric models. It is adaptive in the sense that the number of clusters need not
be pre-specified. More or less clusters are introduced depending on the complexity of the costeffectiveness distribution.
Our work also advances the literature in Bayesian nonparametric (BNP) causal inference. An array
of nonparametric priors have been successfully applied to causal inference problems (Hill, 2011;
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Kim et al., 2017; Roy, Lum, and Daniels, 2017; Xu, Daniels, and Winterstein, 2018; Xu et al., 2016).
For instance, Roy et al., 2018 use an EDP prior to model joint outcome-covariate distributions
and apply the model to causal estimation with missing-at-random covariates. However, modeling
of bivariate counterfactual outcomes using the EDP and GP has not been explored. In CEAs,
heterogeneity in cost-efficacy is typically either ignored in favor of a single, marginal effect estimate
or is explored along pre-defined subgroups (e.g. hispanic males). Methods in the heterogenous
treatment effects literature such as Bayesian Additive Regression Trees (BART)-based procedures
(Hahn, Murray, and Carvalho, 2020; Henderson et al., 2018) and Causal Forests (Athey and Wager,
2019) are distinct from our approach as they focus on estimating individual-level treatment effects.
Moreover, these methods cannot be readily applied to the joint outcome setting with censoring.
Instead, we use the induced clustering of the EDP to propose subgroups in a probabilistically
principled way. We can then describe each subgroup of the joint in terms of its covariate, cost, and
efficacy distributions and use these to motivate future, targeted studies. We propose a “Differential
Subgroup Index” which measures how much of the cost-efficacy heterogeneity is explained by the
EDP’s partitioning of the joint distribution. This helps us assess the meaningfulness of the clusters.
We begin by providing a brief overview of cost-effectiveness and the desirability of causal estimands. We then present our model along with a Markov Chain Monte Carlo (MCMC) algorithm for
posterior inference. We incorporate our model into a g-computation framework for posterior causal
effect estimation under specified identification assumptions. Finally, we outline how the induced
clustering of the EDP can be used to explore heterogeneity. Simulation studies assessing frequentist properties of our causal effect estimates under various censoring scenarios and generating
models are conducted. We end with a cost-effectiveness analysis of chemotherapy and radiation
therapy treatments for endometrial cancer using SEER-Medicare claims data.

3.2. Overview of Relevant Cost-Effectiveness Contrasts
In this paper, we consider a binary treatment setting where assignment is indicated by A ∈ {0, 1}.
The goal of CEAs is to characterize the relative cost-effectiveness of these two treatments - necessitating both a cost and efficacy measure. In many settings, the total cost, Y , includes all costs
accumulated under this treatment - e.g., hospitalization and medication costs incurred due to adverse events. Moreover, costs are typically measured from the payer’s perspective, not the patient’s
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perspective. In single-payer systems like that of the United Kingdom, this would be the National
Health Service (NHS). For older patients in the United States, as in our data analysis to follow, the
payer of interest is typically Medicare. Though lifetime costs is often of interest, many CEAs set a
duration for cost accrual (e.g. 2-year costs) due to follow-up constraints. In this paper, we consider
a survival time effectiveness measure, D. This is the dominant effectiveness measure in cancer
CEAs, the motivating data application of our paper.
A typical observational CEA study follows diagnosed patients after assignment to one of two treatment regimes. After some follow-up period, everyone’s (possibly censored) cost and survival time,
are recorded and various cost-effectiveness contrasts can then be computed. For instance, the
incremental cost effectiveness ratio (ICER) is given as ICER =

E[Y |A=1]−E[Y |A=0]
E[D|A=1]−E[D|A=0] .

This mea-

sures the average cost per unit of effectiveness (increase in survival time). We can also define
a monetary value under each treatment, M V (κ) = Dκ − Y . Here, κ is the “willingness-to-pay”
parameter. It is interpreted as the maximum dollar value the payer is willing to give for a one
unit increase in effectiveness. It is considered a fixed, user-specified value. Here, we will suppress notational dependence on κ by simply writing M V where there is no ambiguity. A treatment with positive M V suggests that accrued gains in life value, κD, are greater than accrued
costs. Health economists often assess cost-effectiveness via the average net monetary benefit,
E[N M B] = E[M V | A = 1] − E[M V | A = 0], where we have again suppressed dependence of
N M B on κ. This contrast is closely related to ICER and can be interpreted as the average difference in monetary value between treatment groups. Note that average NMB can also be written
equivalently as E[N M B] = (E[D | A = 1] − E[D | A = 0])κ − (E[Y | A = 1] − E[Y | A = 0]).
This is linear function of κ with the efficacy differential as the slope and the cost differential as the
intercept. Another related quantity is the Cost Effectiveness Acceptability Curve (CEAC), which is
a curve comprised of P (N M B > 0) plotted for various κ.
However, note that M V and N M B presented above have no causal meaning as treated and untreated subjects may differ systematically in observational studies. This is undesirable because
many policy questions are inherently causal with the goal being to estimate the average costeffectiveness that would have accrued had everyone taken a particular treatment, possibly counter
to fact. Estimation of M V with causal meaning requires (1) an estimate of the joint distribution
of cost and survival time while adjusting for confounders and (2) causal identification assumptions.
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Even if all relevant confounders are measured and included in the model, misspecification of the adjustment model may yield biased estimates of cost-effectiveness contrasts - motivating the need for
robust, nonparametric modeling of the joint. In the following sections we first describe a Bayesian
nonparametric model for the joint outcome conditional on confounders and treatment. We then define a causal N M B as the difference in average potential monetary value that would have accrued
under each treatment. We go on to formulate the identification assumptions required to estimate
these causal quantities using our nonparametric joint model.

3.3. Joint Nonparametric Model for Cost and Survival Time
We consider a binary treatment setting in which n patients are assigned to treatment Ai ∈ {0, 1} at
baseline. Suppose we are interested in contrasting cost-effectiveness over τ periods (e.g. τ = 2
year cost-effectiveness). We observe data D = {Yi , Ti , Xi , δi }i=1:n from this study. Here, Xi =
(Ai , Li ) is a covariate vector that contains the treatment indicator and a vector of q categorical
or continuous pre-treatment confounders, Li . For notational convenience, we proceed without an
intercept, but a 1 can be included as the first entry of Xi . We let Ti = min(Di , Ci , τ ) be the observed
time under study (the minimum of a random right-censoring time Ci , end of study τ , and death
time Di ). Define a censoring indicator as δi = I(Di > min(Ci , τ )) Finally, Yi ∈ Y denotes cost
accumulated through time Ti . The joint distribution can be factored into a distribution for observed
time and cost distribution conditional on time. A joint model follows from specifying “local” models
for each of these two distributions:
Yi | Ti , δi , Xi , ωi ∼ p(Yi | Ti , δi , Xi , ωi )
Ti | δi , Xi , θi , λ0 ∼ λ0 (t) exp(Xi0 θi )

(3.1)

ωi , θi | G ∼ G.
At a particular time, T , cost follows some local distribution p(Yi | Ti , δi , Xi , ωi ) governed by parameters ωi . Survival time follows some local hazard function which is parameterized as having some
baseline hazard, λ0 with covariate effects, θi , multiplying this baseline hazard. Lastly, ωi and θi the covariate effects of the cost and effectiveness model - both follow some joint prior distribution G,
which is unknown. Choice of the local models are application-specific but are not crucial for model
fit, as will become apparent when we discuss the nonparametric priors used for G and λ0 .
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One consideration when choosing the local model is desired predictive support. For instance, if
costs are sufficiently far from zero, we may be willing to set p(Yi | Ti , δi , Xi , ωi ) to a Gaussian over
Y = R with mean and variance ωi = (µi , φi ). The corresponding regression could be specified
as µi = (Ti , δi , Xi )0 βi . If the non-negative nature of costs must be respected, we could instead
specify a log-normal distribution over Y = R+ . For applications with zero-inflated costs, we may
wish to explicitly put positive measure on zero - i.e. setting Y = {0} ∪ R+ . This can be done
by specifying a two-part model Yi | Ti , δi , Xi , ωi ∼ πi δ0 (Yi ) + (1 − πi )f (Yi | Ti , δi , Xi , βi ), where
πi = P (Yi = 0 | Ti , δi , Xi , γi ) is a covariate-dependent model for the probability of cost being zero
(e.g. a local logistic regression) and δ0 is the point mass distribution at 0. In this case, the cost
parameter vector is ωi = (γi , βi ). Oganisian, Mitra, and Roy, 2020 developed a nonparametric
Bayesian estimation procedure for such a two-part model, where f could be either log-Normal or
Normal, using a Dirichlet Process prior.
In (3.1), censored patients contribute to the likelihood through both the cost and survival time
models. In the survival model, they contribute to the likelihood through the survival function in
the usual way, provided that, conditional on covariates, censoring times are independent of survival times. Specifically, the probability distribution of death times can be expressed in terms

of the hazard above, λ(d; θi , X) = λ0 (d) exp(Xi0 θi ), as p(d | θi , λ0 , Xi ) = λ(d; θi , Xi ) exp −

Rd
λ(u;
θ
,
X
)du
. Similarly, the survival distribution can be expressed as P (D > d | Xi , θi ) =
i
i
0
 R

d
exp − 0 λ(u; Xi , θi )du . Censored subjects (δi = 0) contribute to the likelihood via P (D > Ci |
θi , λ0 , Xi ). Failed patients (δi = 1) contribute via p(Di | θi , λ0 , Xi ). In the cost model, dead patients
provide information about the cost distribution at death time p(Yi | T = Di , δ = 0, Xi , ωi ), while
censored subjects inform the model at time of censoring p(Yi | T = Ci , δ = 1, Xi , ωi ).
3.3.1. Nonparametric Priors
We specify the following nonparametric priors on the unknown model quantities, G and λ0 .
G | αω , αθ ∼ EDP (αω , αθ , G0 )
(3.2)
λ0 | b, λ∗0 , ξ ∼GP (bλ∗0 , b, ξ),

Above, EDP denotes the Enriched Dirichlet Process (Wade et al., 2014) prior on G and GP denotes
the dependent Gamma Process prior (Nieto-Barajas and Walker, 2002) on the baseline hazard
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λ0 . These priors are nonparametric in the sense that they are probability measures on infinitedimensional objects - the former over probability distributions and the latter over hazard functions.
Realizations, G, from the EDP are discrete probability distributions centered around a base distribution G0 (ωi , θi ) = G0ω (ωi )G0θ|ω (θi |ωi ) with two concentration parameters, αω and αθ . Some prior
realizations are visualized in the left panel of Figure 3.1. Just as with the Dirichlet Process (DP),
this discreteness induces a posterior clustering of patients. Unlike the DP, the clustering induced
by the EDP is nested. A posteriori, patients with similar cost parameters are clustered together
into what we call ω-clusters. Within each ω-cluster, patients with similar effectiveness parameters
are clustered together (θ-clusters). The EDP prior does not require pre-specification of the number
of clusters. The clustering is data-adaptive, with more clusters being introduced to capture more
complex cost-effectiveness distribution. The posterior model for the joint distribution is an adaptive
nested mixture of cost-effectiveness models - with each component model having the form of the
local model in (3.1), but with different component-specific parameters. In the machine learning
literature, these models are often referred to as “mixture of experts” learners: the data space are
partitioned into homogenous regions, each having its own model that develops “expertise” in that
region. This is in contrast to ensemble learners (e.g. BART and Random Forests), which apply
multiple models to the entire data and combine the results post-hoc.
The GP can be thought of as a prior over the space of hazard functions. Each realization λ0 from
the GP is a hazard function centered around a mean function λ∗0 with concentration parameter b.
Some prior realizations are visualized in the right panel of Figure 3.1. The process is “dependent”
in that it induces a prior AR(1) autocorrelation structure on λ0 : the hazard at time point t is a
weighted average of the hazard at the previous time point and the prior hazard, λ0 . The resulting
shrinkage/smoothness, controlled by hyperparameter ξ, regularizes the empirical estimate of the
baseline hazard - which can be erratic at later time points when the at-risk set becomes small.
These prior choices are motivated by the shortcomings of the standard DP. A potential issue with
specifying G ∼ DP (αG0 ) is that it imposes a single layer of clustering for both cost and effectiveness. Many clusters may be introduced to fit the joint of Y and T if one of these dimensions is more
complex - even if the other is very simple. This makes estimates needlessly variable. The nested
nature of the EDP avoids this by allowing varying number of clusters on each dimension controlled
by separate concentration parameters. Thus, it is possible to introduce a single cost cluster that
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Figure 3.1: Realizations of the Enriched Dirichlet and Gamma Processes. (a) 100 draws of
(θ, ω) ∼ G where G ∼ EDP (10, 10, N2 (0, I2 )). Note the nested discreteness of G causes ties (i.e.
clustering) among the draws: there are 80 other draws with the same ω value as the blue point, but
with different θ values. Twenty three of those 80 also have the same θ value. (b) Gray lines show
50 hazard realizations from a gamma process centered around the hazard of a W eibull(1.5, 2)
distribution. The blue line shows the mean of the 50 realizations.
has many survival time subclusters. Similarly, modeling the baseline hazard separately avoids introduction of excess clusters to fit a potentially complicated function which, for causal estimation
purposes, is just a nuisance parameter. This is also the reason why we opt for a proportional hazard (PH) formulation rather than an accelerated failure time (AFT) approach: PH models clearly
separate the covariate effects from the baseline risk, which we do not want influencing the EDP
mixture.
3.3.2. Posterior Inference using Markov Chain Monte Carlo
Inference for (3.1) is done via MCMC. We follow the general scheme of Neal’s algorithm 8 (Neal,
2000), which introduces auxiliary parameters to sample from the DP posteriors. Roy et al., 2018
used this approach to sample EDP posteriors, though without a Gamma Process update and no
joint outcome considerations. The idea is to introduce latent cluster indicators (the auxiliary parameters) for each subject. Conditional on draws in the previous iteration, each MCMC iteration
then updates clustering indicators conditional on parameters and before updating cluster-specific
parameters conditional on these newly updated indicators. At iteration m, we may have J (m) oc-
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(m)

cupied ω-clusters indexed by j ∈ {1, . . . , J (m) } and, within the j th ω-cluster, we may have Kj
(m)

occupied θ-clusters indexed by kj ∈ {1, . . . , Kj

}. Let c1:n = (c1 , . . . , cn ) be cluster assignment in-

dicators where each ci is a length two vector with first and second entry indicating membership to an
ω-cluster and θ-subcluster, respectively. Throughout, we use the notation va:b , where a < b are integers, to denote the collection (va , va+1 , . . . , vb ) . Let ω[j] represent the cost parameter associated
with cluster j and θ[j,k] represent the effectiveness parameter associated with the k th subcluster of
ω-cluster j. We should strictly denote θ[j,k] as θ[j,kj ] but suppress the subscript throughout wher−i
ever reference is clearly made to the k th subcluster of ω-cluster j. Moreover, define n−i
j and nj,k as

the number of subjects (excluding subject i) currently occupying ω-cluster j and ω-θ cluster (j, k),
respectively, at the current iteration, m. At each iteration m we conduct the following sequence of
conditional posterior updates:
• Update cluster membership:
– Propose parameters for a new θ-subcluster for each existing ω-cluster, {θ[j,K (m) +1] : j ∈
j

1, . . . , J (m) } by drawing from the prior G0 .
– Similarly, propose parameters for new ω-cluster with θ subcluster, {ω[J (m) +1] , θ[J (m) +1,1] }.
(m)

– Conditional on current draws of all cost-effectiveness parameters and λ0 (indicated by
(m)
“−” for compactness), update ci according to the following probabilities:

(m+1)

P (ci

| −, D) ∝
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n−i
j nj,k
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(m)

(m)
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• Update cluster parameters: These require Metropolis-Hastings steps if G0 ω or G0θ|ω are not
conjugate.
– Update each cluster’s cost parameter, ω[j] , by drawing from conditional posterior
(m+1)

ω[j]

(m+1)

∼ p(ω[j] |c1:n

Y

, D) ∝ G0ω (ω[j] )

p(Yi |Ti , Xi , δi , ω[j] )

(m+1)
i|ci
∈(j,·)

– For each j, update all θ[j,kj ] by drawing from conditional posterior
(m+1)

θ[j,k]

(m)

(m)

Y

∼ p(θ[j,k] |c1:n , λ0 , D) ∝ G0θ|ω (θ[j,k] )

(m)

i|ci

(m+1)

• Update baseline hazard, λ0

(m)

p(Ti | Xi , δi , λ0 , θ[j,k] )

∈(j,k)

: This is a multi-step update involving a discretization of the
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time interval [0, τ ] into increments, then modeling the hazard rate in each increment. This is
motivated by the fact that if λ0 follows a Gamma Process, then the hazard rates in any finite
partition of the time interval have Gamma distributions (Nieto-Barajas and Walker, 2002).
Additionally, the latent parameters inducing the AR(1) smoothness across increments are
also updated with a mix of grid sampling and adaptive Metropolis steps. Details are provided
in Appendix B.2.
Note that the induced nested clustering of the EDP is explicitly encoded into this sampler. In the
cluster-update step, a given subject is most likely to be assigned to the cluster with parameters that
yield the highest joint-distribution evaluation (i.e. fit their data the best). Moreover, each subject can
possibly be assigned to a new cost cluster, new effectiveness cluster within an existing cost cluster,
or a new cost-effectiveness cluster. This last event is likely to occur if, for example, the subject
is so unique that random parameter draws from the prior fit that subject’s data better than any of
the existing cluster-specific parameters. Furthermore, note that each term for an existing cluster in
(m+1)

P (ci

= (j, k) | −, D) is an increasing function of the number of patients already assigned to

that cluster. This is the well-known “rich-get-richer” property of the EDP - the a priori favoring of assignment to larger clusters. This prevents over-fitting by penalizing small clusters. After every cycle,
(m+1)

ci

(m+1)

maps each subject to a set of updated parameters (ωi

(m+1)

, θi

(m+1)

, λ0

(m)

(m)

). After a suffi(m)

(m)

cient burn-in period this algorithm produces M draws from the posterior {ω1:n , θ1:n , λ0 , c1:n }1:M .
These can be used to do full posterior inference on any functional of the joint including, as we will
see, causal estimands.
3.3.3. Priors and Hyperparameter Choice
The hyperparameters for the EDP are the base distribution G0 (ωi , θi ) = G0ω (ωi )G0θ|ω (θi |ωi ) and
the concentration parameters αθ and αω . Following previous papers (Oganisian, Mitra, and Roy,
2020; Roy et al., 2018), we use prior independence so that G0 (ωi , θi ) = G0ω (ωi )G0θ (θi ) and set
G0θ (θi ) = N (θ̂P H , νθ ĈP H ). Here, we are centering the cluster-specific covariate effects around the
Cox proportional hazard estimate, θ̂P H . The prior covariance matrix, ĈP H , is diagonal with the
square of the Cox proportional hazard standard error estimates along the diagonal. The parameter
νθ > 0 is a user-specified scalar that controls how tightly or widely dispersed the cluster-specific
effects are around the Cox estimates.
The choice of G0ω (ωi ) depends on the choice of local cost model. Suppose our local model,
p(Yi Ti , δi , Xi , ωi ) is Gaussian, N (µi , φi ) with regression µi = E[Yi | Ti , δi , Xi , ωi ] = (δi , Ti , Xi )0 βi
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and variance φi , where βi is the vector of covariate effects. The full cost parameter vector is
ωi = (βi , φi ) and we could set G0ω (βi , φi ) = N (βi ; β̂, νω Σ̂)IG(φi ; shape = a0 , scale = ŝ2 (a0 − 1).
The vector β̂ is the MLE estimate of the cost regression and Σ̂ is a diagonal matrix with the square
of the standard error estimates along the diagonal. The parameter νω > 0 is user-specified and
controls the tightness of the prior around β̂. Similarly, the Inverse Gamma prior for φi having mean
equal to the empirical outcome variance, ŝ2 =

1
n−1 (Yi

− Ȳ )2 . The user-specified parameter, a0 ,

controls how widely the cluster-specific variances are dispersed around the empirical variance,
with higher values corresponding to a tight prior around the empirical estimate. Finally, we follow
previous approaches (Oganisian, Mitra, and Roy, 2020; Roy et al., 2018) and set Gam(1, 1) (i.e.
flat, uninformative) priors on each of the concentration parameters. These parameters can be
interpreted as prior sample sizes for the cost and effectiveness clusters - higher values on average
lead to more occupied clustering. Thus, this Gamma prior penalizes many occupied clusters, but
has a long tail to allow posterior deviations if demanded by the data.
Finally, we center the Gamma Process prior around a constant hazard function. Specifically, we
compute the Nelson-Aalen estimate of the baseline cumulative hazard, then take the difference
between each point on this curve to obtain the baseline hazard estimate at each time point. We
then compute the average of these hazard rates across time, λ̂. Then, in GP (bλ∗0 , b, ξ) we can set
λ∗0 to be exponential with rate λ̂. Intuitively, this expresses the prior belief of a constant hazard (with
rate in the range of the observed rates). However, if the data disagrees, the posterior will move us
to a richer estimate governed by the data. The parameters ξ and b can be used to calibrate degrees
of informativeness. For example ξ near zero and large b corresponds to an informative prior belief
of a constant hazard. Conversely, values of b near 0 correspond to an uninformative prior.

3.4. Posterior Causal Estimation via g-Computation
Here we describe full posterior inference for various causal estimands expressed in terms of potential outcomes (Rubin, 1978). In scenarios with censored outcomes, causal estimands are typically
formulated under a hypothetical “joint intervention” (Robins, Hernán, and Brumback, 2000) on both
treatment and censoring. Let M V A=a,δ=0 = DA=a,δ=0 κ − Y A=a,δ=0 be the monetary value that
would have accrued over τ periods had the patient received treatment a and not been censored.
The components Da,0 and Y a,0 are the survival time and costs, respectively, that would have been
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observed under treatment A = a had the subject not been censored. The population-level estimand
of interest is Ψ = E[N M B] = E[M V 1,0 ] − E[M V 0,0 ]. This is the average difference in monetary
value that would have accrued over τ periods had everyone in the target population been assigned
to treatment 1 versus treatment 0, and not been censored. In general, interventions in observational CEAs are not random. Instead, they are driven by confounders - factors which both influence
treatment and cost-effectiveness. Thus, E[M V a,0 ] 6= E[M V | A = a, δ = 0] in general, since those
who actually received treatment and remained uncensored may not be representative of the target
population. Suppose, however, that we observe a set of pre-treatment confounders, L. Under the
following extensions of the usual causal identification assumptions, we can identify Ψ:
IA.1 Joint ignorability : (Y a,δ , Da,δ ) ⊥ (A, δ) | L. Conditional on L, censoring and treatment should
be as good as random - being completely independent of the death and costs that would
have accrued under a particular treatment. Omission of unmeasured drivers of both the joint
intervention or cost-effectiveness would result in a violation of this assumption.
IA.2 Joint Consistency : (Y a,0 , Da,0 ) = (Y, D) | A = a, δ = 0. This requires that cost and death time
observed for an uncensored (δ = 0) subject assigned treatment A = a is actually (Y a,0 , Da,0 ).
This could be be violated if, for instance, we had non-compliance to the treatment. Then, a
subject assigned a may not have actually taken a and thus we would not observe Y a,0 .
IA.3 Joint Positivity: 0 < P (A = a, δ = 0 | L) < 1. The joint intervention cannot be deterministic at
any level of L. This could be violated if, for example, all uncensored males received treatment
A = 1 - leaving us with no information on how well uncensored males with treatment A = 0
faired. In these cases, the model may extrapolate the outcome under treatment A = 0 learned
from females onto males. Poor extrapolation could lead to bias.
IA.4 No Joint Interference: (Yia1:n ,δ1:n , Dia1:n ,δ1:n ) = (Yiai ,δi , Diai ,δi ). Here, a1:n and δ1:n are ndimensional vectors containing each subject’s treatment and censoring status. This assumption requires that one person’s joint treatment-censoring intervention cannot impact another’s
cost-effectiveness. It allows us to drop all but the ith element of a1:n and δ1:n . Usually this assumption would be violated in infectious disease exposures or other settings where subjects
cannot be reasonably viewed as exchangeable (one person’s infection status may impact
another’s infection probability).
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Under these assumptions, Ψ is identified via Robins’ g-formula (Robins, 1986)
Ψ(ω1:n , θ1:n , λ0 ) =

Z 

E[M V | A = 1, δ = 0, L, ω1:n , θ1:n , λ0 ]

L

(3.3)

− E[M V | A = 0, δ = 0, L, ω1:n , θ1:n , λ0 ] dP (L)

Details are provided in the Appendix B.1. Above, we have explicitly written Ψ = Ψ(ω1:n , θ1:n , λ0 ) as
a function of the parameters governing the joint cost-effectiveness distribution. This is to highlight
that a posterior distribution over these parameters induces a posterior on the the causal estimand
Ψ. Let each expectation in (3.3) be denoted as µ(a, 0) = E[M V | A = a, δ = 0, L, ω1:n , θ1:n , λ0 ].
Then,

Z

τ

Z

∞

(Dκ − Y )p(Y, T | L, A = a, δ = 0, ω1:n , θ1:n , λ0 )dY dD

µ(a, 0) =
0

(3.4)

0

Where this inner integration is over the joint model we presented in (3.1) with Xi = (Ai , Li ). Note
that conditional on δ = 0, T = D in the joint model and we integrate along the time up until τ resulting in τ -period monetary value. This integration can be done efficiently via Monte Carlo (see
Appendix B.2).
The outer integration over L in (3.3) requires an estimate of P (L). To avoid strong parametric
assumptions, we use a Bayesian bootstrap (Rubin, 1981). That is, we express p(L) as a discrete
Pn
distribution with mass pi at the ith observed confounder vector Li . Specifically, p(L = l) = i=1 pi ·
δLi (l). Here δLi is a point-mass at Li . The Bayesian bootstrap follows from an improper Dirichlet
prior on the weights, p1:n = (p1 , . . . , pn ) ∼ Dir(0, . . . , 0). This yields a conjugate posterior p1:n |
L ∼ Dir(1, . . . , 1) with n−dimensional posterior mean vector E[p1:n | L] = (1/n, 1/n, . . . , 1/n).
At the end of the mth iteration of updates from Section 3.3.2, we have a set of parameter draws
(m)

(m)

(m)

(m)

{ω1:n , θ1:n , λ0 }, which we can use to construct a posterior draw of monetary value µi
E[M V | A = a, δ =

(m) (m)
(m)
0, Li , ωi , θi , λ0 ].

We then take a draw

(m)
p1:n

and construct a draw of the confounder distribution p(m) (L = l) =
both of these into (3.3), yields a draw from the posterior of Ψ
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Pn

(a, 0) =

from the Dirichlet posterior

i=1

(m)

pi

· δLi (l). Substituting

Ψ(m) ≈

n
X

(m)

pi



(m)

µi

(m)

(1, 0) − µi

(0, 0)



(3.5)

i=1

Repeating for iterations m = 1, . . . , M yields M draws from the posterior of the causal τ -period
NMB: {Ψ(m) }1:M . The mean of these draws can serve as a Bayesian nonparametric point estimate
of Ψ and percentiles of the M draws can be used to form credible intervals.
The posterior draws can also be used to compute a point on the CEAC for each κ, P (N M B >
P
1
(m)
> 0). We note that, from this Bayesian perspective, each point on the
0 | D) ≈ M
m I(Ψ
CEAC is a posterior p-value or tail-area probability. If individual-specific estimates are required,
Equation (3.4) can be evaluated for particular Li under both treatments using each of the m posterior parameter draws. The difference would be a draw from the posterior of Ψi = N M Bi (κ),
(m)

denoted Ψi

(m)

= µi

(m)

(1, 0) − µi

(0, 0). In the causal literature, these are variously referred to

as conditional average treatment effects (CATEs) or individual treatment effects (ITEs). Across M
iterations, we would also have subject-level credible intervals for Ψi . The left panel of Figure 3.2
visualizes posterior mean and intervals for each Ψi using an illustrative synthetic example.

3.5. Adaptive Subgroup Discovery
The MCMC scheme of Section 3.3.2 yields posterior draws of latent cost-effectiveness cluster mem(m)

bership, {ci

}1:M . In this section, we propose using these draws to adaptively discover subgroups

of patients with different cost-effectiveness profiles. This is “adaptive” in the sense that the number
of clusters is not pre-specified, but grows or shrinks as the model adapts to the data complexity. Subgroup discovery is a policy-relevant endeavor since current CEA practice tends to focuses
on marginal, population-level analyses - even if there is significant variation in the target population. Existing approaches to heterogeneity Athey and Wager, 2019; Hahn, Murray, and Carvalho,
2020; Henderson et al., 2018 focus on computing ITEs and use post-hoc heuristic procedures to
characterize this heterogeneity across pre-defined subgroups - rather than proposing subgroups
adaptively.
Using the given MCMC outputs for subgroup discovery is challenging for two reasons. First, the
(m)

vector of cluster assignment labels, c1:n , have no meaning across MCMC iterations - making it
difficult to determine the posterior mode partition. This is known as label switching (Stephens,
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2000). To illustrate, consider that a new cost-effectiveness cluster forms in iteration m + 1 and all
subjects previously in another cluster are re-assigned to this new cluster. In this case, even though
the assignment has changed, the underlying composition of the cluster did not. As a solution, we
(m)

propose to keep track of the n × n adjacency matrix C (m) , where the ij th element, Cij , is a binary
indicator of subject i and j being in the same cost-effectiveness cluster at iteration m. Note that this
(m)

is just the vector c1:n re-arranged into a matrix. Taking the elementwise mean of this matrix across
P
the m posterior draws yields a probability matrix P = (1/M ) m C (m) where ij th element, Pij , is
the posterior probability of subject i and j being in the same cost-effectiveness cluster. To get a
(m)

hard clustering assignment, we then search draws, {c1:n }1:M , for the assignment that is “closest” to
P. That is, we search for c∗1:n = arg minm ||C (m) − P||, where || · || is some matrix norm. As in earlier
P
(m)
papers on Bayesian clustering, here we adopt “Binder’s Loss” || · || = i,j (Cij − Pik )2 (Binder,
1978; Dahl, 2006). This essentially approximates the posterior mode of the EDP-induced partition,
P. The middle panel of 3.2 visualizes P from an illustrative synthetic example as a weighted
graph where each subject is a node and the length of vertices connecting two nodes are inversely
proportional to Pij . Subjects with low posterior probability of being in the same cost-effectiveness
cluster are far apart on the graph. Such figures are good tools for assessing uncertainty in posterior
mode assignments, c∗i . For instance, the points between the group of dark red and blue clusters
represent subjects with highly uncertain mode assignments. The covariate effects of these subjects
look just as similar to the well-separated dark blue points as they do to the well-separated dark red
points.
A second challenge with using the assignments for subgroup discovery is that the EDP clusters are
not explicitly designed to cluster on N M B. The clustering is driven by the complexity of the joint
cost-effectiveness distribution. This is necessary for a flexible joint distribution estimate, but may
not translate into meaningful N M B clusters. For instance, consider a bimodal cost-effectiveness
distribution with two groups having very different mean costs. However, the difference in costs between treatment groups in both clusters may be the same. In this case, the EDP will likely introduce
two clusters with similar N M Bs. This begs the question: are the clustering results detecting subgroups with different cost-effectiveness profiles? To answer this question, we propose a posterior
Differential Subgroup Index (DSI) that, at each MCMC iteration, computes the proportion of the
(m)

total variation in the ITEs, Ψi

, that is explained by the cluster partition in that iteration. First, de-
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Figure 3.2: Clustering results from EDP-GP fit using synthetic data with two latent costeffectiveness clusters. Here, EDP-induced clusters on the joint distribution capture differences
in N M B. The left panel shows posterior point and 95% interval estimates Ψi (with κ = 1). Colors
indicate posterior model cluster assignment, c∗1:n . The middle panel visualizes the posterior probability matrix P. The right panel is the posterior distribution of DSI - indicating that about 70% of
the variation in subject-level Ψi is explained by the EDP clustering. However, this need not be the
case. The EDP clusters may be capturing complexities unrelated to NMB. While this is desirable to
obtain a good fit to a complex distribution, it means the clusters have no substantive meaning. The
DSI is necessary to distinguish between these scenarios.
(m)

fine the mean N M B in subject i’s cluster at iteration m: Ψ̄i

=

1
P

j

Then the DSI measure is,
P 
i

DSI (m) = P

(m)

Ψ̄i

(m)
i (Ψi

− Ψ(m)

(m)

I(cj

(m)

=ci

P
)

(m)

(m)

j|cj

(m)

=ci

Ψj

.

2

− Ψ(m) )2

(3.6)

This intuitively plays the same role as a regression R2 statistic. Across the m iterations, we have
a set of draws for this statistic, {DSI (m) }1:M , which reflects our uncertainty about how well the
clustering is capturing heterogeneity in N M B. A posterior distribution for DSI concentrated near 1
suggests that the EDP-induced clustering explains nearly all of the variation in the subject-specific
N M Bs. This implies that the EDP-induced clustering at the joint cost-effectiveness level is capturing variation at the NMB level. The right panel of 3.2 plots the posterior distribution for DSI
for an illustrative synthetic example generated with two cost-effectiveness clusters. We can then
summarize our data along the mode partition, c∗1:n . For instance, in the synthetic example, we
can create a table summarizing the observed costs, survival, and covariate distributions of the two
identified clusters. These can be used to motivate future cost-effectiveness studies targeting these
subgroups. The DSI also provides context for our marginal posterior estimate, Ψ. A high DSI indicates that a marginal estimate is not capturing substantial treatment effect heterogeneity detected
by the EDP posterior.
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3.6. Assessing Frequentist Properties via Simulation
In this section we report results of several simulation experiments exploring the frequentist properties (i.e. bias, coverage, and precision) of our posterior mean and interval estimates for Ψ under a
variety of settings. These results are reported in Table 3.1. We simulate data with one continuous
confounder, four binary confounders, and a binary treatment. We simulate survival times conditional
on treatment and confounders from a Weibull distribution. Survival times are censored by censoring
times that also follow a covariate-dependent Weibull distribution. We simulate an outcome from a
true Y distribution of either a Gaussian or Log-Normal, with confounder- and treatment-dependent
means. Data were simulated under low (5%) and high (20%) covariate-dependent censoring. For
each of these, we simulate under a parametric and bimodal setting. Under the parametric setting,
the joint distribution is unimodal - leading to a simple joint cost-survival distribution. Under the bimodal setting, we simulate data from a mixture of two cost-effectiveness distributions, each having
different covariate effects in the cost and survival time models. In each of these eight settings,
we simulate 200 datasets with 1500 subjects each. Details about the data generation are given in
Appendix B.3.
We include the doubly-robust estimator (DR-SL) of Li et al., 2018 as a comparator. This approach
involves estimating separate models for conditional mean cost and conditional mean survival time
via super learner. Predictions from these models are weighted by the product of the inverse probability of treatment and inverse probability of censoring. We estimate the former using a correctly
specified logistic regression - which suggests the DR estimate will be consistent but may still have
substantial bias in finite samples if the models are inadequate. For the latter, we note that Li et
al. did not consider the covariate-dependent censoring in their analysis. Instead, they estimate the
probability of censoring in both treatment groups separately via Kaplan-Meier. Li et al. suggest
using a discrete-time failure model in situations with covariate-dependent censoring. Here, we contribute to the literature by implementing this suggestion using a logistic regression. In the super
learner libraries, we include regression trees, generalized additive, linear models, as well as elastic
net generalized linear model (GLMnet). As recommended by Li et al., we using the bootstrap BCa
interval for inference.
For the EDP-GP, we run using independent Gaussian base distributions for G0 that are null centered
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Table 3.1: Simulation Results. Average bias of posterior mean NMB (as discussed in Section 3.4 )
along with coverage and average width of 95% credible/confidence interval (CI) is reported for EDPGP model. Point estimate is reported for DR-SL along with coverage and width of 95% bootstrap
BCa interval. Bias is reported as a proportion of the truth. Censoring rate was 5% in the low setting
and 20% in the high setting. Willingness-to-pay is set to κ = 1. Results are across 200 simulated
datasets with N = 1500 subjects each.
Simulation Setting
Y Dist.
Joint Dist. Cens.
Low
Parametric
High
Gaussian
Low
Bimodal
High
Low
Parametric
High
Log-Normal
Low
Bimodal
High

Bias
-0.002
-0.002
-0.01
-0.01
-0.02
0.004
-0.004
0.03

EDP-GP
Coverage
0.94
0.97
0.94
0.94
0.92
0.96
0.98
0.92

Width
0.11
0.12
0.13
0.14
0.13
0.14
0.11
0.12

Bias
-0.001
0.003
0.11
0.16
-0.001
-0.01
0.02
0.06

DR-SL
Coverage
0.95
0.95
0.60
0.40
0.96
0.96
0.94
0.90

Width
0.18
0.30
0.64
0.77
0.12
0.13
0.18
0.20

with flat priors, relative to the data variance. Importantly, we use a local conditional Gaussian
model for Y . We set λ∗0 to an exponential (constant) hazard. Additional details on DR-SL and
EDP-GP settings are provided in Appendix B.3. To summarize, the unimodal setting with Normally
distribution Y is the most favorable setting for our method since the Gaussian data generating
model matches the local Gaussian model we specify. In principle, all of these settings are quite
favorable to the DR-SL method since we correctly specify the propensity score model. The logNormal setting is the least favorable to our method since our local Gaussian model is misspecified.
Notice that in all censoring and Y distribution settings, the parametric data generating process
yields low bias and close to nominal coverage for both methods. This is as expected since both
are highly flexible models, they should perform well in simple settings. Note however, that the
models diverge in the more complicated, bimodal setting. In the bimodal log-Normal setting, the
DR-SL exhibits higher bias with a larger interval width relative to EDP-GP. Similarly, in the bimodal
Gaussian setting, the DR-SL model exhibits particularly high bias - 11% and 16% in the low and
high settings, respectively. The main challenge with DR-SL is that the underlying super learner fails
to capture biomodality in the cost-effectiveness joint distribution. In contrast, the EDP partitioning
picks up the bimodality - modeling each mode with separate parameters to attain a better overall
fit. Finally, note that EDP-GP intervals tend to be narrower across settings.
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3.7. Cost-efficacy of Endometrial Cancer Treatment
We apply our BNP method to assess the cost-effectiveness of adjuvant chemotherapy (CT) versus
radiation therapy (RT) for the treatment of endometrial cancer and compare our results to the DRSL estimate. The target population of interest are women over the age of 65 who were diagnosed
with endometrial cancer before undergoing hysterectomy. Within three months after hysterectomy,
patients are assigned to either adjuvant RT or CT. We select a cohort of women over the age of
65 who were diagnosed with endometrial cancer between 2000 and 2014 in the SEER-Medicare
database. The first treatment after three months of diagnosis was recorded. A maximum of τ =
24 months of follow-up after hysterectomy was available in this data cut. Total costs accrued by
Medicare (including inpatient, outpatient, hospice, and pharmaceutical costs) were recorded along
with their survival/censoring status. Covariates which are known drivers of treatment assignment
(age, comorbidities, cancer stage) were extracted. Table 3.2 displays summary statistics for the
sample. Notably, the 2-year survival is slightly lower in the CT arm (93% vs. 94.5%), and average
total costs higher in the CT arm (51.3 vs. 42.6). This suggests worse cost-effectiveness for CT
relative to RT. However, there is significant uncertainty associated with these numbers that should
be quantified. Moreover, the cohorts differ substantially in terms of observed characteristics at
treatment assignment. For instance, the radiation arm has a greater proportion of patients with
baseline International Federation of Gynecology and Obstetrics (FIGO) stage of IB - which is more
severe than IA and I-NOS. Similarly, RT harm has fewer comorbidities - with 57% (vs. 54%) having
Charlson Comorbidity Index of zero. These differences could differentially affect adjuvant therapy
assignment and cost-efficacy.
We use our EDP-GP approach to compute posterior point and interval estimates for NMB while
adjusting for differences in observed covariates. We specify the local cost distribution, p(Yi |
Ti , δi , Xi , ωi ), to be a log-normal distribution with parameters ωi = (βi , φi ). The local regression
is

E[Yi | Ti , δi , Ai , Li , ωi ] = exp (1, Li , Ai , Ti , δi )0 βi + φi /2
This local log-normal distribution respects the non-negative nature of costs, while allowing us to
capture skewness. In the model, Li includes household income, Charlson index, and FIGO. FIGO
is included as a categorical covariates, while the others are treated as continuous. We let A = 1
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Table 3.2: Sample Characteristics: Mean and sample standard deviations reported for continuous
covariates. Counts and proportions reported for categorical covariates. Standardized mean differences (SMD) are provided. Typically SM D > .1 indicate large differences. Monetary amounts are
in thousands of 2018 U.S. Dollars.

Total Accrued Costs ($)
2-yr Survival Prob.
Age (years)
Household Income ($)
Charlson Index
0
1
2
≥3
FIGO Stage
I-NOS
IA
IB
II/II-NOS

Radiation
(N= 3,827 )
42.6 (36.8)
94.5
73.6 (6.2)
60.3 (28.8)

Chemotherapy
(N= 245 )
51.3 (39.7)
93.0
73.2 (6.3)
65.6 (34.0)

2176 (56.9)
1056 (27.6)
342 (8.9)
253 (6.6)

131 (53.5)
65 (26.5)
30 (12.2)
19 (7.8)

353 (9.2)
1162 (30.4)
1780 (46.5)
532 (13.8)

23 (9.4)
128 (52.2)
64 (26.1)
30 (12.2)

SMD
.23
.06
.17
.12

.5

indicate assignment to chemotherapy with radiation being reference.
We set prior G0 as discussed in Section 3.3.3: G0ω (βi , φi ) = N (β̂, Σ̂)IG(a0 , φ̂(a0 − 1)). Here, β̂ are
OLS estimates using log(Y ) as the outcome and Σ̂ = diag(1, .012 , . . . , .012 ). Note the latter appears
overly informative, but is actually fairly wide on the exponentiated scale. That is, a prior variance of
1 implies that mean costs as large as exp(1 · 1.96) ≈ 7 times the empirical mean cost are plausible.
Similarly, a prior variance of .01 implies covariate effects of as large as 2% = 1 − exp(1.96 ∗ .01) are
a priori plausible in the absence of data. For φ, note that the variance of the log-Normal random
variable, Z, is V ar[Z] = (eφ − 1)E[Z]2 , which implies φ = log[V ar[Z]/E[Z]2 + 1]. This motivates
setting φ̂ = log[ŝ2 /ȳ 2 + 1], where ŝ2 and ȳ are the marginal variance and mean of the observed
cost values. We set a0 = 1000, which anchors the prior around the empirical estimate. For the
effectiveness model we again follow Section 3.3.3 and set G0θ (θi ) = N (θ̂P H , I). We center the GP
priors around an empirical estimate λ∗0 (t) = λ̂ ≈ .001 with b = 2000 and ξ = 4000. Here, ξ is on the
order of the sample size - signifying strong AR(1) smoothing. The value b is about half of ξ - putting
equal a priori weight on the prior hazard λ∗0 (t) and the previous hazard at time t − 1.
We run three MCMC chains in parallel for 5,000 iterations and discard the first 3,000 draws of each
chain as burn-in. We initialize each chain with different numbers of initial cost and effectiveness
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Figure 3.3: Posterior estimates of (left panel) NMB for various willingness-to-pay for each additional
month of survival, κ. The posterior distribution of DSI in (middle panel) shows that about 15% of
the variation in the individual-level NMBs is explained by the EDP induced clustering. This suggests
the treatment effect may be relatively homogeneous and the NMB is a good overall average effect
measure. The right panel plots the posterior baseline hazard curve along with 95%, 90%, and 80%
credible bands in successively darker shades. Notice that posterior estimate is smoother version
of the empirical estimate hazard in red. It is a posterior compromise between the empirical hazard
and the prior constant hazard.
clusters and check that the chains converge to each other regardless of this initialization. This
yields a total of 6,000 draws which we use for posterior inference. Other details and assessments
of convergence are provided in Appendix B.4.
We estimate a 2-year NMB of chemotherapy over radiation to be −$14.5 thousand, with 95% CI
[−$16.6, −$12.7]. This assumes a willingness-to-pay of about κ = $4167/month, or $50, 000/year of
life gained - which is standard in cost-effectiveness analyses. This is roughly consistent with the
unadjusted comparison in Table 3.2, where average total costs among chemotherapy patients was
higher by about $9, 000. The left panel of Figure 3.3 shows average NMB as a function of κ for
various κ values. Recall that by definition NMB is a linear function of κ. The intercept at κ = 0
shows an NMB that captures differences in cost only (efficacy has zero value). The negative yintercept here reflects that even if we do not value efficacy, chemotherapy is more expensive than
radiation after covariate adjustment. The negative slope of the curve reflects that adjusted efficacy
(i.e. survival benefit) of chemotherapy is lower. However, the slope here is quite small, suggesting
a very small difference in efficacy. This is consistent with unadjusted results - recall from Table 3.2
that 2-year survival is slightly lower among chemotherapy patients.
In terms of clustering, we compute c∗1:n as given in Section 3.5 and find that about 86% of the
observations are grouped into two posterior mode clusters. However, in the middle panel of Figure
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3.3 we see that only about 15% of the variation in the individual-level NMBs is explained by the EDPinduced partition - which suggests these clusters are not very meaningful for cost-effectiveness.
This indicates low posterior evidence of treatment effect heterogeneity, suggesting average NMB
may fairly characterize the cost-effectiveness profile. Finally, the right panel of Figure 3.3 shows
the posterior estimate of the baseline hazard. Since continuous covariates were normalized, this
represents the hazard among patients with average household income and age with Charlson index
of zero and FIGO II/II-NOS. This has no explicit causal interpretation but is illustrative of the Gamma
process. Notice our posterior has moved away from the constant hazard prior and towards the
empirical (Nelson-Aalen) estimate shown in red. The informative AR(1) shrinkage results in a
smoother posterior curve that penalizes large swings in the empirical hazard.
For comparison, we also ran the DR-SL approach where propensity score model, mean survival
time model, and mean cost model were all estimated using super learner. Regression trees, GLMnet and GLM were included as candidate learners and 95% BCa intervals were estimated using
5,000 bootstrap iterations. For willingness-to-pay κ = $4167/month, DR-SL estimates a 2-year average NMB of −$11.8 with 95% CI [−$19.1, −$6.0] in thousands. This is similar to our estimate
of −$14.5 [−$16.6, −$12.7], but the DR interval is wider. More details on the DR-SL implementation are given in Appendix B.4, including a full plot of average NMB from DR-SL as in Figure 3.3.
For even large willingness-to-pay values of up to 300 thousand USD per year, both approaches
find a negative NMB with intervals excluding zero. This supports the relative cost-effectiveness of
radiation over chemotherapy adjuvant therapy over two years.

3.8. Discussion
Cost-effectiveness is statistically challenging due to the complexities of the joint distribution of cost
and survival time, such as skewness, censoring, and multi-modalities. Moreover, estimation of
policy-relevant estimands with causal interpretation is complicated by confounding in observational
studies. Robust causal inference for cost-effectiveness requires flexible modeling that accounts
for these complexities while adjusting for confounders. In this paper, we outlined a nonparametric
Bayesian solution that leverages the Gamma and enriched Dirichlet process priors to model the
joint distribution of cost and survival time. We proposed cost-effectiveness estimands with causal
meaning and identified them under suitable causal assumptions. We showed how our model can
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be used in a Bayesian g-computation procedure that draws from the posterior of the causal effect.
Finally, we show that the partition induced by the EDP can be used to explore cost-effectiveness
heterogeneity and introduced the DSI diagnostic statistic for assessing how well this partition captures heterogeneity.
In simulations, we demonstrated that our procedure has adequate frequentist properties (bias,
coverage, etc.) in a variety of scenarios. In complex settings, it can be comparable and, at times,
outperform existing doubly-robust methods. Across almost all settings, the EDP-GP produces NMB
estimates with narrower interval widths relative to the DR-SL estimates. In the data analysis, the
DR-SL approach also yields wider intervals. One driver of this is the relative inefficiency of the
DR-SL approach. This method only uses data from patients who are not censored and weights
their contributions by the inverse probability of being uncensored. In contrast, our method uses
censored patients, since they still inform the total cost distribution at their observed time. Another
feature with the DR-SL is that it is a weight-based estimator (weighted both by inverse probability
of treatment and censoring), which are known to be quite variable if the probability of treatment are
near the bounds within subgroups. Since the EDP-GP approach is model-based, it provides more
smoothing under these conditions. Finally, the bootstrap inference procedure used in the DR-SL
approach can be difficult to implement in practice, where sparsity among categorical covariates
leads to the occasional pathological bootstrap resample (e.g. with rank deficient matrix). This is in
contrast to full posterior inference via the Bayesian bootstrap which can be more stable.
Finally, we see at least two avenues of future work and extensions. First, in our paper, we consider a setting with a single baseline treatment. This allows us to estimate the cost-effectiveness
of baseline treatments, which are highly relevant in many settings. However, we may also wish to
estimate the cost-effectiveness of time-varying treatment regimes, in addition to the effect of the
initial baseline treatment. Flexible causal estimation in these settings is more complex and should
be explored. Second, there has been much work on improving the computational scalability of posterior inference on Dirichlet process models, including both approximate inference via Variational
Bayes and parallel MCMC procedures. Future work developing scalable inferential procedures for
joint-modeling with EDPs can be useful.
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CHAPTER 4
T HE H IERARCHICAL B AYESIAN B OOTSTRAP

FOR

H ETEROGENOUS T REATMENT

E FFECT E STIMATION
4.1. Introduction
Estimation of heterogeneous treatment effects - i.e., effects within strata of some other relevant
variable - is popular in causal inference. These estimands are especially relevant in scenarios
where treatment effects vary substantially in the population. In these scenarios, an overall estimate
averaged across strata may suggest a negligible treatment effect even if there is substantial benefit
within a particular stratum. Such effects can be identified under rather standard causal assumptions
(no unmeasured confounding, positivity, etc.) and computed using standardization in the pointtreatment setting. Within each stratum, standardization involves averaging a stratum-specific regression model adjusting for confounders and treatment over the distribution of confounders within
that stratum. Fully Bayesian approaches to standardization, and causal estimation broadly, have
been growing in popularity. For instance, BART regression models were used in early work by Hill
(2011) to compute marginal effects and subsequently by Zeldow, Lo Re III, and Roy (2019), Hahn,
Murray, and Carvalho (2020), and Henderson et al., 2018 to compute individual treatment effects.
Other Bayesian nonparametric (BNP) priors such as Dirichlet process (DP) and variations such as
the enriched DP and dependent DP regressions have also been used to do full posterior inference
on marginal treatment effects. For instance, such methods have been developed for computing effects under zero-inflation (Oganisian, Mitra, and Roy, 2020), in the presence of missingness, (Roy
et al., 2018), in mediation scenarios (Kim et al., 2017), for censored survival outcomes under competing risks (Xu et al., 2020), and to compute causal quantile effects (Xu, Daniels, and Winterstein,
2018).
To perform standardization, regression models must be averaged over the confounder distribution
of the target population. For instance, Hill averages the BART over the empirical distribution when
computing marginal effects. This is a flexible approach as it makes no modeling assumption about
the distribution. However, it is unsatisfying from a Bayesian point of view since it uses a fixed
plug-in estimate and variability of this estimate does not flow through to the posterior of the causal
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effects. To address this, Wang et al. (2015) and Nethery, Mealli, and Dominici (2019) used the
Rubin’s Bayesian bootstrap (BB) (Rubin, 1981). Broadly, this approach models the confounder
distribution as a point-mass distribution with unknown mass/weight at each observed confounder
value. Posterior inference is done on these unknown weights and variability propagates through to
the causal effects of interest.
The popularity of the BB for marginal estimation has lead to its adoption for heterogenous average
treatment effect (HTE) estimation. These are average treatment effects within strata of some other
variable. For instance, Roy, Lum, and Daniels (2017) evaluate the effect of antiretroviral therapy
on various outcomes among HIV-positive patients with and without recent alcohol use. They use
independent BBs to estimate the confounder distributions of recent alcohol users and non-users
separately. Taddy et al. (2016) are concerned with estimating effects of a large A/B testing experiment among “new” and “old” platform users. Again, these use separate BB estimates within these
two strata. More recent work by Boatman, Vock, and Koopmeiners (2020) attempts to do causal
estimation in a setting where data are collected from several “supplemental sources” in addition to
a “primary” data source. They then estimate a causal effect within the “primary” stratum by averaging a BART regression over a BB estimate of the confounder distribution in the primary source,
separate from the other sources.
Though common, using separate BBs for HTE estimation is not ideal - especially when some strata
are sparse. For instance, in our motivating data analysis we target the marginal effect of proton
versus photon chemoradiotherapy on adverse event risks. The question of interest is how the effect
varies across different cancer types for which chemoradiotherapy is the standard-of-care. This is
complicated as some cancer types (e.g. lung) may be rare in the sample, giving us little data
on the confounder distribution within these strata. By construction, the BB places zero mass on
confounder values unseen within this stratum - even if this is due to small samples and not due to
an a priori belief that unseen values are impossible. While plausible covariate values for lung cancer
patients may have been observed for, say, brain cancer patients, stratum-specific BBs have no way
of borrowing this information. Our main contribution is the construction of a hierarchical Bayesian
bootstrap (HBB) prior for estimating stratum-specific confounder distributions in precisely such a
setting. Based on the Hierarchical Dirichlet Process (HDP), our approach allows for a principled
borrowing of confounder information across strata. For large strata, the HBB posterior shrinks to the
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stratum-specific BB. For small strata, it is shrunk more heavily towards values seen in other strata.
This approach (1) maintains the flexibility of the BB (we make no parametric assumptions about
the confounder distributions), (2) provides room for efficiency gains via the induced shrinkage, and
(3) is fully conjugate and agnostic to the choice of outcome model. This last property makes it
compatible for several of the popular outcome modeling approached mentioned earlier.
Several notable modifications to the bootstrap have been proposed which are distinct from our
work. For instance, Makela, Si, and Gelman (2018) developed a two-stage Bayesian bootstrap
for a cluster-randomized study setting. Here, clusters/strata are sampled and then individuals are
sampled within a cluster. A key problem here is how to account for strata that exist, but are never
sampled. This is distinct from our problem where strata are known and fixed and the issue is to
borrow information across them. Approaches such as “bag-of-little bootstraps” (Barrientos and Pea,
2020; Kleiner et al., 2014) have been proposed with the goal of scaling bootstrap to large datasets.
The idea run separate bootstraps on sub-samples, then combine in such a way as to approximate
the overall bootstrap distribution. However, we are not concerned with estimating the overall data
distribution, but stratum-specific distributions. Finally, several “smoothed” bootstraps have been
developed (Efron and Gong, 1983; Silverman and Young, 1987; Wang, 1995). The view here
is that the Efron’s bootstrap is sampling from the empirical distribution that places uniform mass
on each observed data value. This point-mass distribution is convoluted with a kernel to induce
smoothness. While indeed a step in the right direction, it is unsatisfactory from the perspective of
HTE estimation. We could, for instance, estimate stratum-specific smoothed bootstrap distributions.
This will indeed place some mass on the unseen values, but this mass is allocated via an ad-hoc
kernel, rather than informed by data in the other strata. Specification of this kernel is also a hurdle,
which BB does not face. As we will see, however, we can provide a probabilistic motivation for the
smoothed bootstrap as an improper case of the HBB.
In the next section, we introduce some notation and motivate the causal problem more precisely
before outlining the HBB and related computation. After, we will discuss simulation studies assessing the performance of the HBB relative to dominant approaches in the causal literature under a
variety of settings. We end with an analysis contrasting the risk of adverse events for proton versus
photon therapies across various cancer types.
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4.2. Background and Motivation
Suppose we observe outcome Y for subjects assigned to treatment A ∈ {0, 1} along with some
confounders L = (W, V ) that are measured pre-treatment. These are variables which we believe to
be drivers of both treatment and outcome. In the HTE setting, this set often consists of V - a discrete
variable taking on values v ∈ {1, 2, . . . , K} along which we wish to make causal comparisons - and
variables W which we would like to average over. The levels of V are sometimes constructed
using multiple covariates - e.g. V marking all combinations of discrete V1 and V2 . Using potential
outcomes notation (Rubin, 1978), one popular causal estimand is the heterogeneous, or stratumspecific, average treatment effect (HTE) Ψ(v) = E[Y 1 − Y 0 | V = v] - the average difference in
outcomes had everyone in the stratum V = v taken treatment 1 versus 0. Note this is distinct from
the target of individualized treatment effect (ITE) estimation, which are individual-level effects.
While we could estimate E[Y | A = a, V ] with observed data, in general E[Y | A = a, V ] 6=
E[Y a | V ]. That is, the average outcome among subjects treated with A = a in V may not be
the same as the average outcome had everyone in V taken treatment A = a. This is due to
confounding: treated subjects may be a non-representative subset of the patients in stratum V (e.g.
systematically sicker and, therefore, more likely to have worse outcomes). Under well-known causal
identification assumptions, we can estimate Ψ(v) by integrating the difference in stratum-specific
outcome regressions over the conditional distribution of W (see Web Appendix A in Supporting
Information)
Z
Ψ(v) =

n
o
E[Y | A = 1, V = v, W ] − E[Y | A = 0, V = v, W ] dPv (W )

(4.1)

W

where Pv (W ) = P (W | V = v). This formula is known as standardization - a special case of the
g-formula (Robins, 1986) in the point-treatment setting. The same general approach can be used
to compute an overall average treatment effect (ATE) Ψ = E[Y 1 − Y 0 ] by integrated the outcome
regression over the joint P (L) = P (W, V ). The estimand Ψ(v) is more relevant than Ψ in settings
where, due to variability within the population, the ATE is not a meaningful measure of the treatment
effect.
Suppose we observe n independent subjects with data, D = {Yi , Ai , Wi , Vi }1:n . Let Sv = {i : Vi =
v} contain the indices of subjects in stratum V = v and let nv denote the cardinality of Sv such that
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n=

P

v

nv . Bayesian inference typically proceeds by obtaining a posterior over E[Y | A, V, W ] and

Pv (W ) which together induce a posterior over the target Ψ(v). As discussed in the introduction,
many BNP models exist for the former. Efficient estimation of the latter via the HBB is the chief
objective of this paper, but first we review some popular alternatives. One approach is to plug in the
P
empirical distribution P̂v (w) = n1v i∈Sv δWi (w) - where δx (·) denotes the degenerate distribution
at x. For compactness we sometimes denote these as simply Pv and δx . This places uniform mass
of 1/nv on each confounder vectors observed in stratum v.
To our knowledge, Wang et al. (2015) first proposed using Rubin’s Bayesian bootstrap (BB) (Rubin,
1981) over this empirical approach and it has since become popular as it accounts for variability
in the empirical estimate (Nethery, Mealli, and Dominici, 2019; Saarela et al., 2015; Xu, Daniels,
and Winterstein, 2018). To summarize the BB, it models the covariate distribution as Pv (w) =
P
v
v
v
i∈Sv πi δWi (w), but unlike the empirical approach the weights, π = {πi }i∈Sv , are considered
unknown parameters that completely determine Pv . A prior over these these weights is then a prior
P
v
over Pv . Noting that the weight vector lives in the simplex, π v ∈ {Rnv : πiv > 0 ∀i ∈ Sv ,
i∈Sv πi =
1}, BB places an improper Dirichlet prior over this space π v ∼ Dir(0nv ), where 0nv is the nv dimensional zero vector. This is a conjugate model with posterior π v | {Wi }i∈Sv ∼ Dir(1nv ), where
1nv is the nv -dimensional vector of ones. Note that this is done for each V = v, separately. This
is the approach used for HTE estimation in the Bayesian causal inference literature by Boatman,
Vock, and Koopmeiners (2020), Roy, Lum, and Daniels (2017), and Taddy et al. (2016). This
common approach does have several advantages. First, it retains the flexibility of the empirical
distribution. Note that the posterior expectation of each πiv is 1/nv . Second, unlike the empirical
estimate, variability in this estimate flows through to the posterior of Ψ(v) since the weights are
not fixed at 1/nv . Third, it is computationally easy to sample due to conjugacy and, fourth, it is
agnostic to the choice of outcome model. However, it becomes problematic for sparse strata where
few values of W are observed. Under the BB, Pv assigns zero probability to values of W that are
unseen in stratum v. This is undesirable because there are many values that we may think are a
priori plausible. Indeed, we may observe such values in other strata. Since the BB estimates of Pv
are done independently, the posterior estimate of Pv cannot borrow this information - yielding less
stable estimates of Ψ(v). In essence, the proposed HBB retains these desirable properties of the
BB while addressing the small-strata shortcomings by “partially pooling” the estimates of Pv .
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4.3. The Hierarchical Bayesian Bootstrap
Let W v = {Wi }i∈Sv denote the observed confounders in stratum v and let W = {W v }v=1:K denote
the full set of confounders. We model W v as following an unknown distribution W v | Pv ∼ Pv
and propose a prior for Pv that borrows information across V . The DP is a stochastic process
that generates random, discrete distributions. Due to its flexibility and conjugacy, it has become a
popular prior for unknown distributions in Bayesian analysis. Suppose we place a DP prior on each
Pv , denoted Pv ∼ DP (αP0v ). The realizations of Pv are centered around a “mean” distribution of
P0v , with α > 0 controlling the dispersion of these realizations around P0v . This is flexible because
the posterior of Pv under a DP is a compromise between the prior mean, P0v , and the empirical
P
distribution in stratum V = v, i∈Sv δWi (w), with relative weight controlled by α. However, each
Pv is centered around its own P0v , preventing any borrowing of information across strata. This
motivates the hierarchical DP (HDP) of Teh et al. (2006), which centers the Pv around a common
mean distribution P0 and adds a DP hyperprior on P0 . We note that while the following development
may seem rather involved, the actual posterior computation will be fully conjugate and efficient.
Under the HDP prior, the full model for the covariates is
Wi | Pv ∼ Pv for i ∈ Sv
Pv | α, P0 ∼ DP (αP0 ) for v = 1, . . . , K

(4.2)

P0 | γ, P∗ ∼ DP (γP∗ )
The DP hyperprior on P0 implies that the random P0 are discrete - allocating mass to atoms. Due
to this discreteness, the distributions Pv have support on the same atoms as P0 but allocate mass
differently across these atoms in a way that is local to V . Since the DP is conjugate, the posterior of
P
Pv conditional on P0 is another DP: Pv | P0 , α, W v ∼ DP (αP0 + i∈Sv δWi ). Similarly the marginal
Pn
posterior of P0 is also a DP: P0 | W ∼ DP (γP∗ + i=1 δWi ). For the Hierarchical BB, we set γ = 0
in (4.2) and denote this prior on Pv as Pv | α ∼ HBB(α). This yields posterior under the HBB(α)
Pv | P0 , α, W v ∼ DP (αP0 +

X
i∈Sv

n
X
P0 | W ∼ DP (
δ Wi )
i=1
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δWi )
(4.3)

With γ = 0, P0 are random distributions centered around the empirical distribution P0 | W ∼
Pn
DP ( i=1 δWi ) This distribution is discrete with an atom at each of the n observed Wi . A P0
can be drawn from this posterior by drawing a vector of weights π1:n ∼ Dir(1n ), where π1:n =
Pn
(π1 , π2 , . . . , πn ). This draw of P0 can then be represented as P0 = i=1 πi δWi . Note that this is
exactly the BB. However, now we have an additional layer of uncertainty as the stratum-specific
Pn
P
distributions must be drawn around this P0 : Pv | P0 , α, W v ∼ DP (α( i=1 πi δWi ) + i∈Sv δWi ).

Figure 4.1: Draw from posterior of Pv under prior Pv ∼ HBB(2) with simulated scalar Wi for
n = 90 subjects from V = 1, 2, 3. These 90 atoms are represented by vertical bars with colors
indicating stratum of the atom. The height of the lines represent probability mass drawn from the
HBB posterior. Left panel: a draw of P0 - recall this is centered around the empirical distribution
(i.e. line 2 in (4.3) ). The next panel shows a draw from the Dirichlet Process posterior of Pv
conditional on this draw of P0 - i.e. line one of (4.3). Note that P1 , P2 , and P3 place positive mass
on all observed atoms. For instance, independent BB estimates of P2 would put place 0 mass on
all atoms but the red - unlike the third panel.
Again, conditional on a draw of P0 , each Pv is a discrete distribution with atoms at each of the
observed n points in the entire sample. Combining like terms in the summations, however, we see
that atoms observed in stratum V = v have a weight of απi + 1 - higher than the weight on atoms
unseen in stratum V = v, which is απi . To see this, note that in expectation (over many draws of
Pv ), the posterior distribution of W v can be represented as a Pólya Urn (Blackwell and MacQueen,
1973):
n
X
X
α
1
Pv (W = w | P0 , α, W ) =
(
πi δ Wi ) +
δWi
α + nv i=1
α + nv
i∈Sv
o
X
1 nX
=
απi δWi +
(1 + απi )δWi
α + nv
v

i∈S
/ v

(4.4)

i∈Sv

Again due to the finitely many atoms, we can draw a Pv from this posterior by drawing from an ndimensional Dirichlet distribution with the ith concentration parameter being απi for i ∈
/ Sv and
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1 + απi for i ∈ Sv . Intuitively, this can be seen as adding an additional α subjects from the
marginal distribution into stratum V . These “pseudo-subjects” can take on any observed value
in the marginal, even if they are unobserved in the stratum - thus, borrowing information. As with
the posterior update for P0 , a draw from this Dirichlet distribution yields an n-dimensional set of
Pn
v
weights π1:n
and thus a draw of Pv is given by Pv (w) = i=1 πiv δWi . Note that in the above we
used a common α across strata. This is without loss of generality, as each stratum can have its
own αv without changing the results. We will turn to specification of these hyperparameters after
discussing computation.
4.3.1. Posterior Computation via MCMC
Here we describe posterior HTE inference under a HBB(α) prior for Pv via Markov Chain Monte
Carlo (MCMC). At each iterations m = 1, . . . , M , we
(m)

(m)

1. Obtain a posterior draw of P0 by drawing weights π1:n ∼ Dir(1n ) then forming P0
Pn
(m)
δWi (w).
i=1 πi
(m)

2. For each v = 1, . . . , K, obtain a posterior draw, Pv
drawing
(m)
απi

v(m)
π1:n

∼

(m)
Dir(ηn ),

if i ∈
/ Sv and

where

(m)
ηn

(m)

, conditional on P0

(w) =

. We do this by

is the n-dimensional vector with element i being

(m)
(1 + απi )

(m)

if i ∈ Sv . Note the sum of the elements in ηn
Pn
(m)
v(m)
now forms a draw of Pv (w) = i=1 πi
δWi (w).

is α + nv . This

Now to estimate the HTEs, suppose we also have M posterior draws of the regression E[Y |
A, W, V ], denoted by µ(m) (A, W, V ). This can be from any model. For instance, in a GLM this could
(m)

be µ(m) (A, W, V ) = g −1 (β0

(m)

+ W 0 βw

(m)

+ V 0 βv

(m)

+ βA A) where g −1 is the inverse link function.

This could also be a posterior draw µ(m) (A, W, V ) = f (m) (A, W, V ) where f (m) is the posterior draw
of a sum-of-trees model under a f ∼ BART prior. To estimate the HTE, we include a third step
(m)

3. Integrate over HBB draw of Pv from Step 2, Pv
Ψ(m) (v) =

Z

.

n
o
µ(m) (1, Wi , v) − µ(m) (0, Wi , v) dPv(m) (W )

W

=

n
X

v(m)

πi

n
o
µ(m) (1, Wi , v) − µ(m) (0, Wi , v)

i=1
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(4.5)

Repeating this procedure for each of the draws yields a set of M draws from the posterior of Ψ(v),
{Ψ(m) (v)}1:M , for each stratum v = 1, . . . , K. Note that the Wi from all subjects contribute to
Ψ(m) (v). However, values from the stratum and values outside the stratum are weighted differently
v(m)

according to πi

.

4.3.2. Some Limiting Cases and Hyperparameter Choice
Here we consider the limiting behavior of the HBB by analyzing (4.4) conditional on P0 (w) =
Pn
i=1 πi δWi and the choice of hyperparameter. Note that for α = 0, the first term in line one of
P
(4.4) disappears and our estimate reduces to Pv (W = w | P0 , α, W v ) = n1v i∈Sv δWi . This is the
empirical distribution within stratum v and represents a completely unpooled estimate where values
of W unseen in stratum v have no mass. Thus, there is no borrowing of information. This is also
the posterior mean of the BB estimate of Pv . Now consider the other extreme where α >> nv . In
Pn
this case (4.4) reduces to Pv (w | P0 , α, D) = i=1 πi δWi - the BB estimate of the entire marginal
distribution (over V ) that places expected mass E[πi ] = 1/n on each observed value of W in the
entire sample. That, is we have completely pooled all the stratum-specific distributions. The parameter α controls the posterior compromise between these extremes for a particular stratum. The
idea of partial-pooling is to balance the bias-variance tradeoff, with fully pooled estimates favoring
reduction in variance over potential increase in bias and fully unpooled estimates favoring a reduction of bias over potential increase in variance. Of course, partial-pooling by its nature may induce
bias, especially if the confounder distributions in the sub-populations are very different. While it
may be tempting to view the introduction of a user-specified parameter α as a limitation, we have
just shown above that the dominant BB approach already makes a very strong prior choice of α = 0
- implicitly favoring the completely unpooled scenario, even if some partial pooling to reduce variability is sensible. The explicit introduction of α is more sensible as we do not lock users into this
strong prior.
Hyperparameter guidance:

To guide decisions about α, recall that we can interpret α > 0 as adding an additional α pseudosubjects from the marginal distribution of W to the nv subjects in stratum v. Higher α places
more weight on the pseudo-subjects - who may have values unseen in stratum V = v (i.e. more
shrinkage towards the marginal). The relative mass on a point seen within the stratum relative
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to an unseen point is approximately ρ =

1+α/n
α/n

=

n
α

+ 1. This is seen in (4.4) when substituting

πi with its posterior expectation of 1/n. For example, if we add α = n pseudo-subjects, then on
average the atoms seen in stratum v are about as likely as the atoms not seen in stratum v. This
is fairly aggressive shrinkage. For some M > 0, one option is to set α =
relative weight of ρ =

nv
M

n·M
nv

which implies a

+ 1. We should now subscript this parameter as αv as it is stratum-specific

depending on nv - but we omit this notation where there is no ambiguity. Here, M is user-specified
and can be interpreted as the minimum desired sample size in each stratum. This may partially be
set depending on the number of confounders we are integrating over and the complexity of the joint
distribution. For instance, with well-behaved, standard joint distribution (e.g. multivariate Gaussian),
M = 30 subjects within a stratum may be sufficient to estimate the distribution. On the other hands,
if the covariates are complex, skewed, and multimodal we may need a larger M to obtain a good
nonparametric estimate such a distribution. Note that strata with size nv << M implies ρ ≈ 1 which
corresponds to heavy shrinkage. Conversely, for large strata with nv >> M , ρ gets larger - placing
increasingly more weight on atoms within stratum v only. This reduces shrinkage proportional to nv .
Figure 4.2 depicts draws from the posterior of Pv under a prior Pv ∼ HBB(nM/nv ) with synthetic
data. Note that strata that are more sparse (relative to M ) have distribution draws that are more
heavily shrunk towards the marginal. However, we place positive mass on all points observed in
the sample. While in some ways it could be more satisfying to specify a prior over α, this would

Figure 4.2: Draw from posterior of Pv under prior Pv ∼ HBB(nM/nv ) with n = 300 scalar confounders simulated for v = 1, 2, 3 strata. Here we set M = 30. Note that for stratum V = 1 we have
far greater observations than M and so the draw of P1 places most mass on atoms seen in this stratum. Stratum 2 has size slightly larger than M and so places ρ = 58/30 + 1 ≈ 3 times more weight
on atoms seen in the stratum. Stratum 3 only has 10 subjects, and so places ρ = 10/30 + 1 ≈ 1
equal weight on all atoms. This last case represents heaviest shrinkage.
complicate the posterior computation with a non-conjugate update. The existing BB’s popularity
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due in large part to its conjugate Dirichlet updates and keeping α user-specified maintains this
important property.
The smoothed bootstrap as a limiting case:

The smoothed bootstrap has been proposed as one way of placing mass on unseen values of W . In
this section, we briefly show how this is a limiting case of the HBB(α) prior on a mixing distribution


P
i
when α → 0. The smooth bootstrap estimate of Pv is given by P̂v (w) = n1v i∈Sv Kh w−W
.
h
Smoothness is induced by convoluting a user-specified symmetric kernel, Kh , with the empirical
distribution and the parameter h controlling smoothness. For concreteness, suppose the kernel is
w−Wi
i
chosen to be standard Normal Kh ( w−W
h ) = N ( h ; 0, 1). Then this bootstrap model is a mixture

of nv kernels centered around each observed Wi with variance h2 . The mixing distribution is the
empirical distribution giving weight 1/nv to each mixture component. Now consider a Bayesian

R
mixture model with unknown mixing distribution Pv , written as P (w | Pv ) = W Kh w−W
dPv (W ).
h
Here, W are random with distribution Pv and w is a particular value. With an HBB(α) prior on the
mixing distribution, recall that the mean of Pv is given via the Pólya Urn in (4.4). Plugging this urn
expression in for Pv yields
Z
P (w) =

Kh
W

o
X
w − W n α
1
P0 (W ) +
δWi (W )
h
α + nv
α + nv
i∈Sv

In the improper limit as α → 0, the left term in the Pólya Urn goes to 0. Distributing the kernel and noting that the integral over W is non-zero only at each observed Wi , we get P (w) =


P
w−Wi
1
. This is exactly the smoothed bootstrap estimate P̂v . Thus, we have a probK
h
i∈S
nv
h
v
abilistic motivation for the smoothed bootstrap via the HBB, formally linking our work with this previous result. Later in the discussion we elaborate on how this link may motivate future work on a
“smoothed” HBB.

4.4. Simulation Experiments
In this section we assess the behavior of the HBB relative to other approaches under a variety of
settings via simulation. In all settings, we simulate 1000 datasets with n = 300 observations from
K = 4 strata of varying sparsity. On average, the strata counts are n1 = 120, n2 = 90, n3 = 60,
n4 = 30. Thus, stratum 4 is the most sparse stratum and stratum 1 is the least sparse. In each
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simulated data set, we simulate a vector, W , of 10 confounders for each subject conditional on
stratum V . The treatment indicator A itself is simulated as a function of stratum membership and
confounders. We simulate a binary outcome model conditional on V , W , and A from a logistic
model. In the true outcome model, each stratum has a different (conditional) treatment effect,
leading to true HTEs that vary across strata. These represent challenging scenarios with several
confounders and small samples that are often encountered in applied work.
For each simulated dataset, we use a correctly specified Bayesian logistic regression with wide,
null-centered Gaussian priors. This is to focus attention on the confounder distribution models.
After posterior sampling for the regression, we compute a causal risk difference, Ψ(v) = E[Y 1 |
V = v] − E[Y 0 | V = v], by integrating the regression over the confounder distribution model
under both treatment interventions and taking the difference. We integrate over four confounder
distribution models: the empirical distribution, the stratum-specific BB estimate, the HBB, and the
oracle. By “oracle” we mean a Monte Carlo integration over draws from the true stratum-specific
confounder distribution. For the HBB, we set Pv ∼ HBB(nM/nv ) with M = 100 in all settings.
We assess the bias, variance, coverage, and precision of posterior estimates for Ψ(1) (the effect in
the least sparse stratum) and Ψ(4) (the effect in the most sparse stratum) across simulation results
in Table 4.1. Additional details about the simulation study can be found in Web Appendix C in
Supporting Information.
In the first setting, we consider a relatively simple multivariate Gaussian generating distribution for
W , which does not vary across V . In this “homogeneous Gaussian” setting, we see little difference
in performance among the 4 methods in the least sparse stratum (V = 1). This is desirable as we
would want the HBB to perform similar to other methods in such populous stratum. In the sparse
stratum (V = 4), the HBB has slightly lower bias with lower MSE (equal up to three decimal places).
Notably, the HBB borrows information across strata to yield, on average, smaller interval lengths
than the BB (.46 v .478) while maintaining nominal coverage of around 95%. Note that the BB
produces a wider interval than the empirical distribution as well (.478 v .459) this is because the BB
accounts for uncertainty in the confounder distribution estimate.
The second setting considers a more difficult scenario where W is marginally generated from a
location mixture of Gaussians. Each W is generated from a 10-dimensional multivariate normal but
with different mean for each stratum. Thus, borrowing information from different strata is expected
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Table 4.1: Simulation results: MSE, absolute bias, empirical variance of the posterior mean along
with the width and coverage of the 95% credible interval across 1,000 simulation runs. MSE is computed as average of the squared difference between posterior mean and truth across simulations.
Empirical variance is computed as the variance of the 1000 posterior means. In general, the HBB
trades off bias for gains in efficiency, leading to overall reduction in MSE for sparse strata. Performance is generally similar to BB in more populous strata. The performance is particularly good in
the complicated Gamma mixture setting, where stratum 4 has too few observations from the tail of
the Gamma-distributed W to estimate P4 (W ) reliably via BB. The HBB, however, is able to borrow
tail values observed in the other strata.
Model
Stratum 1

Stratum 4

Stratum 1

Stratum 4

Stratum 1

Stratum 4

Stratum 1

Stratum 4

MSE
Bias Variance Interval Width
Setting 1: Homogeneous Gaussian
Empirical 0.005 0.007
0.005
0.256
BB
0.005 0.007
0.005
0.260
HBB
0.005 0.007
0.005
0.258
Oracle
0.005 0.008
0.005
0.255
Empirical 0.013 0.002
0.013
0.459
BB
0.013 0.002
0.013
0.478
HBB
0.013 0.000
0.013
0.460
Oracle
0.013 0.000
0.013
0.457
Setting 2: Gaussian Mixture
Empirical 0.005 0.003
0.005
0.261
BB
0.005 0.003
0.005
0.264
HBB
0.005 0.007
0.005
0.253
Oracle
0.005 0.004
0.005
0.259
Empirical 0.014 0.003
0.014
0.465
BB
0.014 0.003
0.014
0.484
HBB
0.011 0.018
0.010
0.440
Oracle
0.013 0.000
0.013
0.463
Setting 3: Bernoulli Mixture
Empirical 0.007 0.005
0.007
0.310
BB
0.007 0.005
0.007
0.312
HBB
0.007 0.012
0.006
0.300
Oracle
0.007 0.006
0.007
0.310
Empirical 0.023 0.010
0.022
0.577
BB
0.023 0.010
0.022
0.584
HBB
0.021 0.032
0.020
0.544
Oracle
0.022 0.011
0.022
0.575
Setting 4: Gamma Mixture
Empirical 0.005 0.013
0.005
0.268
BB
0.005 0.013
0.005
0.272
HBB
0.006 0.022
0.006
0.288
Oracle
0.005 0.009
0.005
0.260
Empirical 0.032 0.092
0.023
0.587
BB
0.032 0.092
0.023
0.592
HBB
0.011 0.002
0.011
0.405
Oracle
0.010 0.018
0.009
0.371
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Coverage
0.930
0.930
0.933
0.928
0.944
0.951
0.948
0.945
0.938
0.939
0.941
0.934
0.949
0.952
0.950
0.957
0.933
0.936
0.930
0.931
0.953
0.953
0.945
0.95
0.942
0.947
0.934
0.950
0.904
0.907
0.943
0.933

to come at the expense of more increased bias. Indeed, in stratum 4 we see that absolute bias is
about six times higher for HBB relative to BB (.018 v .003), however variation is also reduced (.01 v
.014) leading to about a 20% reduction of MSE (.011 v .014). The HBB interval is narrower relative
to BB (.440 v .484) while maintaining close to nominal coverage. In stratum 1 we see equivalent
MSE across methods.
In the third setting, we consider the case where W is comprised of independent Bernoulli realizations - with separate probability vectors for each stratum. Each vector can have 210 possible values,
but there are far fewer than 210 observations in any of the stratum. This complicates estimation of
P v(W ). In the sparse stratum V = 4, we see the HBB has nearly three times higher absolute bias
(.032 v .01) but has reduced variability (.020 v .022). The MSE is reduced by about 8% (.021 v
.023) with the HBB. Notably, the HBB interval is, on average, narrower while maintaining close to
nominal coverage. While, in any stratum, we observe far fewer than the 210 possible values of W ,
the HBB is able to borrow values seen in other strata.
Lastly, in the fourth setting we consider an even more complicated scenario where W is generated
from a 10-dimensional location mixture of Gamma distributions. Each stratum has a different mean
and, importantly, skewness. This scenario is designed to assess the tail-behavior of the HBB. As
shown in Table 4.1, the HBB performs especially well in this complicated scenario. In stratum 4, the
MSE, bias, and variance are lower than the BB. Intervals are narrower and coverage is closer to the
nominal rate (94.3%). The small sample size in stratum 4 leads to too few covariate observations
from the tail of the skewed Gamma to have a reliable nonparametric estimate of P4 (W ). This leads
to poor BB estimates. However, in this setting the HBB borrows realizations from the tail in other
strata - leading to a better estimate of P4 (W ).

4.5. Adverse Event Risk of Proton versus Photon Therapy
In this section we conduct posterior inference for casual contrasts of proton versus photon therapy
among patients being treated for various locally-advanced cancers. For the cancers under consideration, standard-of-care therapy is a combination of chemotherapy and radiation - known as
concurrent chemoradiotherapy (CRT). However, many modalities of radiation exist. The most common modality used in CRT has been photon radiation. In recent year, proton radiation therapy has
become more accessible alternative to patients as barriers to access have eased and health sys-
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tems have adopted the necessary technology. The idea of proton therapy is to deliver radiation in
a more targeted way to the cancer site, while being less damaging to healthy tissue relative to photon. Observational data were collected from n = 1468 adult patients diagnosed with non-metastatic
cancer and treated with CRT at the University of Pennsylvania Health Systems from 2011-2016.
Our data includes assigned treatment to CRT with either proton or photon radiation, several confounders measured at the time of treatment initiation, as well as the count of adverse events for a
follow-up period of 90 days after treatment initiation. All patients in the sample had complete followup for at least 90 days. Previous research on this data (Baumann et al., 2020) has focused on the
comparative risk of adverse events for patients on proton versus photon radiation. One hypothesis
is that the more targeted nature of proton therapy will lead to fewer adverse events. Importantly, the
differential risk may vary across cancer types. To address these questions, we conduct two analyses. In the first, we estimate a causal incidence difference between proton and photon patients
across cancer type strata using a Poisson GLM for the adverse event count. In the second, we
estimate of causal odds ratio for risk of any adverse event nonparametrically using BART. In the
process we illustrate how the HBB can be combined with both parametric and nonparametric models for different outcome types. It can also be used to estimate different marginal causal contrasts
(incidence differences, odds ratios, risk ratios, etc).
4.5.1. Parametric Model for Causal Incidence Difference
In this setting, our outcome is a count of adverse events over the 90-day follow-up, Y ∈ {0} ∪ Z+ .
We observe data across K = 8 cancer types (e.g., lung, head and neck, and esophagus/gastric)
indicated by V . Let A = 1 denote proton while A = 0 denote photon. Finally, let W be a vector of confounders including baseline age, race, sex, body-mass index (BMI), insurance plan, and
charlson comorbidity index (a measure of baseline health status). We specify a conditional Poisson
outcome model with the regression below. We adjust for race, sex, and insurance plan as categorical covariates. BMI, age, and charlson index are included as continuous covariates. More details
on specification and prior choices are given in Web Appendix D in the Supporting Information. The
mean of the Poisson distribution is modeled as E[Yi | Ai , Wi , Vi = v] = exp{β v + Wi0 η v + Ai θv }.
Though parametric, such models are common in practice. Note we allow coefficients to vary
across strata. Our target of interest here is the causal incidence difference within each stratum
Ψ(v) = E[Y 1 | V = v] − E[Y 0 | V = v]. A negative value indicates lower incidence of adverse
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Poisson Outcome Models

BART Outcome Models

Figure 4.3: Posterior mean and 95% credible interval estimates of stratum-specific causal contrasts
under Poisson model (left) and BART (right). For both models, we set minimum desired sample size
of M = 100. The abbreviations are gynecological (gyn), pancreas/duodenum/hepatobiliary (p/d/h),
esophagus/gastric (e/g), and head/neck (h&n). Similar strata definitions were used in previous
clinical studies (Baumann et al., 2020) and may be justified by anatomical closeness of affected
organs.
events due to proton therapy relative to photon. To obtain this, we integrate the above regression
over various estimators of Pv (W ). The left panel of Figure 4.3 displays results under three different
estimates of Pv - including the HBB (with M = 100), BB, and the empirical distribution of W in each
stratum. While the estimates for Ψ(v) are largely similar across strata, note the HBB intervals are
typically slightly shorter. Similarly, the point estimates are typically higher in these strata. This may
partially reflect the trading off of increasing biased for reduced variability, as demonstrated in the
simulations. However, these simulation results were averages across many runs. In any single data
analysis, HBB need not produce narrower intervals.
Interpreting posterior estimates of Ψ(v) in Figure 4.3, we see that the proton and photon therapies’
effect on adverse event incidence are largely comparable across cancer type - with posterior distributions centered either near zero or very wide around 0 (as indicated by 95% credible intervals).
Of course, these causal interpretations are subject to the validity of the required identification assumptions discussed earlier and in Web Appendix A. Moreover, these inferences are conditional on
the very rigid parametric assumptions. For instance, it assumes linear (on log-scale) and additive
covariate effects, in addition to a poisson outcome distribution. In the next section, we consider a
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nonparametric estimation via BART.
4.5.2. Nonparametric Inference for Causal Odds Ratio via BART
Here we illustrate how the HBB can be used in conjunction with a nonparametric model for a binary
outcome to obtain HTEs more robust to model misspecification. In this context let Y ∈ {0, 1} be a binary indicator of any adverse event over the 90-day followup period. Then, we specify a conditional

Bernoulli model for Y with regression E[Yi | Ai , Wi , V = v] = Φ fv (Wi , Ai ) with prior fv ∼ BART
for v = 1, . . . , K. This is the probit specification of BART outlined in Chipman, George, and McCulloch (2010). Above, Φ is the standard Normal distribution function and fv ∼ BART is shorthand
PJ
for the sum-of-trees model fv (Wi , Ai ) = j=1 gjv (Wi , Ai ) with J trees, gjv . BART is characterized
by a prior on the structure of each tree, gjv , consisting of terminal node parameters, splitting rules,
and tree depth. Here we estimate stratum-specific models, with separate BART priors on each
function. Thus, for each stratum v, we can get posterior draws of fv under each treatment A = a.
In this case our target is the stratum-specific causal odds ratio Ψ(v) =

E[Y 1 |V =v]/(1−E[Y 1 |V =v])
E[Y 0 |V =v]/(1−E[Y 0 |V =v]) .

Values of Ψ(v) less than one indicate lower risk of any adverse event due to proton therapy, relative to photon. Using standardization, we can compute each expectation by integrating Φ(fv (W, a))
over Pv (W ).The right panel of Figure 4.3 displays posterior results for Ψ(v) under three different
estimate of Pv - including the HBB (with M=100), BB, and the empirical distribution of W in each
stratum. We notice that while point and interval estimates are generally similar across strata, the
HBB intervals are somewhat narrower. However, according to these results, there is little posterior
evidence for a reduction of adverse event risk due to proton therapy. While point estimates of the
odds ratios are below one across strata, there is significant posterior uncertainty about the direction
and magnitude of these effects, as indicated by the wide 95% credible intervals mostly overlapping
one.

4.6. Discussion
The confounder distribution is a key unknown that must be estimated flexibly when making causal
inferences. It is still more important in the context of HTEs where some strata are too sparse to
allow reliable nonparametric estimation. In this paper we show that straightforward application of
the Bayesian bootstrap can be improved upon in these scenarios with the HBB. The proposed HBB
shares covariate information across strata to achieve more stable stratum-specific causal estimates.
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The approach is computationally tractable, compatible with arbitrary outcome models, and makes
no parametric assumptions about the distributions. As shown in the data analysis, it can be used
to compute a variety of marginal causal contrasts.
We emphasize that potential applications of the HBB go beyond estimation of stratum-specific
average causal effects. For instance, another popular causal estimand is the average treatment
effect on the treated (ATT). This is defined as the average difference in potential outcomes among
those assigned treatment. A Standardization-type procedure can be used here as well and requires
integrating a regression over the distribution of confounders among the treated, P (W | A = 1). If
there are too few treated subjects to get a reliable nonparametric estimate of this distribution, it may
be reasonable to borrow covariate information from untreated subjects, P (W | A = 0), by shrinking
towards the marginal via the HBB.
Lastly, our discussion of the connection between the HBB and the smoothed bootstrap motivates
an extension to a “smoothed HBB”. In Section 4.3.2, an HBB(0) prior on the mixing distribution
corresponds to a smoothed bootstrap within a stratum but prevents borrowing of information. We
could in principle set α > 0. In this case, the posterior becomes a hierarchical DP mixture of Kh thus borrowing information across strata while modeling the distribution as a smooth mixture. If, for
instance, Kh is a Gaussian kernel, we speculate the strength of the shrinkage could be informed by
the L − 2 distance in covariate values across strata. While such distance-based shrinkage would
be appealing, posterior computation for such a mixture model is much more involved - requiring
updating the kernel parameters - and requires good default choices of Kh . An advantage of the
HBB is that we require no specification of distance metric/kernel and maintain computational ease.
However, this extension would be interested to pursue in the future.
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CHAPTER 5
D ISCUSSION

AND

C ONCLUDING R EMARKS

This dissertation developed (BNP) techniques for estimating causal effects in a variety of complicated observational data settings. The common thread of these methods is the joint emphasis on
flexible estimation and uncertainty quantification. Nonparametric priors over the high-dimensional
models presented in this work allow us to model observed data objects with only very minimal
assumptions about the data generating mechanism. This greatly reduces the risk of bias due
to misspecification that is common in parametric modeling procedures. Simultaneously, the fully
Bayesian nature of our models allows for posterior uncertainty quantification over the models and
the causal estimates.
This joint emphasis on uncertainty and flexibility supplies BNP methods with some of the best
elements of classical statistics (typically concerned with the former) and machine learning (typically
concerned with the latter). In fact, many BNP methods can be thought of as leveraging a latent
probability model that underlies a given heuristic machine learning algorithm. This view has led to
developments such as Bayesian additive regression trees (BART), which is a probabilistic analogue
of regression tree-based algorithms. Similarly, the DP mixtures used in this dissertation can be
thought of as probabilistic analogues of “mixture-of-experts” models used in machine learning.
Other well-known methods in machine learning such as least absolute shrinkage and selection
operator (LASSO) and Ridge regression can be motivated as maximum a posteriori inference under
specific priors (double exponential in the first case and Gaussian for the latter).
Indeed, interest in BNP methods have seen a revival in computer science and machine learning under the guise of “probabilistic machine learning.” While this term has many usages in the literature,
Ghahramani, 2015 describes it as “the probabilistic approach to modeling uses probability theory
to express all forms of uncertainty.” He writes that “probability distributions are used to represent all
the uncertain unobserved quantities in a model (including structural, parametric, and noise-related)
and how they relate to the data. Then the basic rules of probability theory [presumably, Bayes’
rule] are used to infer the unobserved quantities given the observed data.” Section 2 of that piece
discusses the role of nonparametric priors in detail. Similarly, Murphy, 2021 describes probabilistic
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machine learning as “..machine learning, but from a probabilistic perspective. Roughly speaking,
this means that we treat all unknown quantities ... as random variables, that are endowed with probability distributions...”. From a statistics perspective, we can recognize this exactly as the Bayesian
approach to inference, but with the added flexibility of nonparametric Bayes that go back to at least
Ferguson, 1973.
Separately, the causal inference literature has increasingly focused on flexible semiparametric estimation of target quantities and moved away from parametric modeling. Before these advances,
the approach was typically reversed: parametric models were fit to data and researchers tried to
back out estimates of causal parameters from those models. One issue with this approach is that if
the parametric model is incorrect, then estimators of the causal effects based on transformations of
the parameters would have little meaning. Modern causal inference techniques - such as the ones
employed in this dissertation - begin with the causal target of interest, identify them as a functional
of observed data objects, then model those objects with minimal assumptions about their structure. In our case, we leverage BNP models of these observed-data objects. While these models
have a high-dimensional parameter set that are difficult to interpret, the downstream causal effect
estimates they form have a concrete causal interpretation under clearly specified assumptions.
The rising interest of nonparametric Bayes in machine learning coupled with the emphasis on semiparametric estimation in causal inference inspires optimism about the future of Bayesian nonparametric causal inference. These includes causal inference in dynamic treatment regime settings,
sensitivity analyses for violations of causal assumptions, and and instrumental variable methods in
the presence of unmeasured confounding - to list just a few.
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APPENDIX A
A PPENDICES

FOR

C HAPTER 2

A.1. Derivation of Posterior Quantities
A.1.1. Conditional Posterior
The conditional posterior of ωi can be expressed up to a proportionality constant as
p(ωi |ω1:(i−1) , D) ∝ p(D|ω1:i )p(ωi |ω1:(i−1) )
X
α
1
p(D|ω1:i )G0 (ωi ) +
p(Dj |ωj )I(ωi = ωj )
α+i−1
α + i − 1 j<i
Z
α
∝
p(ωi |Di , G0 )
p(D|ω1:i )dG0 (ωi )
α+i−1
ωi
X
1
+
p(Dj |ωj )I(ωi = ωj )
α + i − 1 j<i

∝

(A.1)

The second line follows by substituting the Pólya Urn scheme for p(ωi |ω1:(i−1) ). The last line follows
from the fact that p(ωi |Di , G0 ) =

R p(D|ω1:i )G0 (ωi ) .
p(D|ω1:i )dG0 (ωi )
ω
i

A.1.2. Posterior Predictive Distribution
Causal inference using standardization is based on the posterior predictive mean of the outcome
under some intervention A = a. Denote this as ỹ a . Letting tildes denote posterior predictive draws
throughout,

a

Z

Z Z

p(ỹ |D) =
ω1:n

l̃

p(ỹ a |˜l, ω̃, ω1:n , D)p(˜l|ω̃, ω1:n , D)p(ω̃|ω1:n )p(ω1:n |D) dω̃ dL̃ dω1:n

(A.2)

ω̃

Conventionally, we assume that that ỹ a ⊥ ω1:n , D|ω̃ and ˜l ⊥ ω1:n , D|ω̃. That is, conditional on
new parameter draws, the new outcome draw is independent of previous observations and their
parameters.

a

Z

Z Z

p(ỹ |D) =
ω1:n

l̃

p(ỹ a |˜l, ω̃)p(˜l|ω̃)p(ω̃|ω1:n )p(ω1:n |D) dω̃ dL̃ dω1:n

ω̃
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(A.3)

Assuming ignorability and consistency hold,

p(ỹ a |D) =

Z

Z Z

ω1:n

l̃

p(ỹ|A = a, ˜l, ω̃)p(˜l|ω̃)p(ω̃|ω1:n )p(ω1:n |D) dω̃ dL̃ dω1:n

(A.4)

ω̃

Recall that ωi |ω1 , . . . , ωi−1 from the Pólya Urn Blackwell and MacQueen, 1973
i−1

ωi |ω1:(i−1)

X
1
α
G0 (ωi ) +
I(ωi = ωj )
∼
α+i−1
α + i − 1 j=1

Substituting i = n + 1 yields
n

ω̃|ω1:n ∼

α
1 X
I(ω̃ = ωj )
G0 (ω̃) +
α+n
α + n j=1

Substituting this into Equation A.4 yields,

p(ỹ a |D) =

Z

Z Z

ω1:n

Z

l̃

ω̃

Z hZ

=
ω1:n

l̃

ω1:n

+

l̃

1
α+n

n
i
α
1 X
G0 (ω̃) +
I(ω̃ = ωj ) p(ω1:n |D) dω̃ dL̃ dω1:n
α+n
α + n j=1

p(ỹ|A = a, ˜l, ω̃)p(˜l|ω̃)

ω̃
n Z
X

1
α + n j=1
Z h
Z
α
+

=

h
p(ỹ|A = a, ˜l, ω̃)p(˜l|ω̃)

α
G0 (ω̃)dω̃
α+n

i
p(ỹ|A = a, ˜l, ω̃)p(˜l|ω̃)I(ω̃ = ωj )dω̃ p(ω1:n |D) dL̃ dω1:n

ω̃

Z

p(ỹ|A = a, ˜l, ω̃)p(˜l|ω̃)G0 (ω̃)dω̃
α + n ω̃
n
i
X
p(ỹ|A = a, ˜l, ωj )p(˜l|ωj ) p(ω1:n |D) dL̃ dω1:n
j=1

(A.5)
Integrating the above over y yields the posterior predictive mean
a

Z

E(ỹ |D) =
ω1:n

Z h
l̃

1
+
α+n

Z
α
E(ỹ|A = a, ˜l, ω̃)p(˜l|ω̃)G0 (ω̃)dω̃
α + n ω̃
n
i
X
E(ỹ|A = a, ˜l, ωj )p(˜l|ωj ) p(ω1:n |D) dL̃ dω1:n

(A.6)

j=1

We can evaluate these integrals via Monte Carlo. Assume we have t = 1, . . . , T draws from the
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(t)

posterior ω1:n ∼ p(ω1:n |D). How to obtain these draws is the subject of Web Appendix B. For each
(t)

posterior draw, we propose a new set of parameters from the prior ω0 ∼ G0 . We also take several
(t)
draws from p(˜l | ωi )

A.1.3. Posterior Predictive Propensity Score
We can use the model to estimate the propensity score for each subject i using the posterior
predictive probability of treatment conditional on subject i’s covariates.

R R
p(Ã, l, ω̃, ω1:n |D) dω̃ dω1:n
p(Ã, l|D)
P (Ã|L̃ = l, D) =
= ω̃R ωR1:n
p(l|D)
p(l, ω̃, ω1:n |D) dω̃ dω1:n
ω̃ ω1:n
R R
p(Ã|l, ω̃)p(l|ω̃)p(ω̃|ω1:n )p(ω1:n |D) dω̃ dω1:n
= ω̃ ωR1:nR
p(l|ω̃)p(ω̃|ω1:n )p(ω1:n |D) dω̃ dω1:n
ω̃ ω1:n

(A.7)

Again, substituting the Pólya Urn distribution,

 α

Pn
1
p(Ã|l, ω̃)p(l|ω̃) α+n
G0 (ω̃) + α+n
j=1 p(Ã|l, ω̃)p(l|ω̃)δωj (ω̃) p(ω1:n |D) dω̃ dω1:n
 α

R R
Pn
P (Ã|l, D) =
1
p(l|ω̃) α+n
G0 (ω̃) + α+n
j=1 δωj (ω̃) p(ω̃1:n |D) dω̃ dω1:n
ω̃ ω1:n

 α R
R
Pn
1
p(Ã|l, ω̃)p(l|ω̃)G0 (ω̃) dω̃ + α+n
j=1 p(Ã|l, ωj )p(l|ωj ) p(ω1:n |D) dω1:n
ω1:n α+n ω̃
 α R

R
Pn
=
1
p(l|ω̃)G0 (ω̃) dω̃ + α+n
j=1 p(l|ωj ) p(ω̃1:n |D) dω1:n
ω1:n α+n ω̃
R R
ω̃

ω1:n

(A.8)

(t)

Again, given T posterior draws ω1:n indexed by t, we can perform a Monte Carlo evaluation of the
integral
T
1X
P (Ã = 1|l, D) ≈
T t=1

α
α+n

R
ω̃

Pn
(t)
(t)
1
p(Ã = 1|l, ω̃)p(l|ω̃)G0 (ω̃) dω̃ + α+n
j=1 p(Ã = 1|l, ωj )p(l|ωj )
R
Pn
(t)
α
1
j=1 p(l|ωj )
α+n ω̃ p(l|ω̃)G0 (ω̃) dω̃ + α+n
(A.9)
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A.2. Metropolis-in-Gibbs Sampler and Relabeling Strategy
We use a Metropolis-in-Gibbs sampler for posterior inference. First, introduce latent cluster indi(t)

cators for the n subjects at iteration t of the algorithm, c1:n . Let K(t) be the set of unique cluster
labels at iteration t. In this iteration, each ci may take on one of K (t) unique values, indexed by k.
(t)

(t)

(t)

(t)

(t)

(t)

Associated k th cluster is a set of cluster specific parameters ωk = (γk , βk , φk , ηk , θk ).
The MCMC procedure alternates between updating the cluster-specific parameters, ωk , conditional
on c1:n . Then updates c1:n conditional on ωk . The procedure is given in Algorithm 1.
Algorithm 1 Metropolis-in-Gibbs Posterior Sampler for Zero-inflated DP Mixture
(0)

1:

Initialize c1:n to K (0) initial clusters with unique labels K(0) .

2:

Initialize parameters ωk for each of these clusters.

3:

for t=1:T do

(0)

4:

Update Cluster-specific Parameters

5:

for k in K(t−1) do

6:
7:
8:
9:
10:

(t)

(t−1)

Q
(t−1)
, D) ∝ i|yi >0,ci =k N (yi |x0i β, φk
) · G0 (ω)
Q
(t)
(t)
(t)
φk ∼ p(φ|βk , D) ∝ i|yi >0,ci =k N (yi |x0i βk , φ) · G0 (ω)
Q
(t)
θk ∼ p(θk |D) ∝ i|ci =k p(li |θk ) · G0 (ω)
Q
(t)
ηk ∼ p(ηk |D) ∝ i|ci =k Ber(Ai |expit(m0 ηk )) · G0 (ω)
Q
(t)
γk ∼ p(γk |D) ∝ i|ci =k Ber(zi |expit(x0 γk )) · G0 (ω)

βk ∼ p(β|φk

(t)

11:

Conditional on ωk for all k ∈ K(t−1) , update c1:n

12:

Propose a new cluster with parameters drawn from the base distribution, ωnew ∼ G0

13:

for i=1:n do
Update to existing cluster...

14:

(t)

(t)

P (ci = k|c−i , {ωk : ∀k ∈ K(t−1) }, D) ∝ p(Di |ωk ) ·

P

I(ci =cj )
α+n

j6=i

...or to the newly proposed cluster.
15:

(t)

P (ci 6= k, ∀k ∈ K(t−1) | c−i , {ωk : ∀k ∈ K(t−1) }, D) ∝ p(Di |ωnew ) ·

α
α+n

In practice we assume prior independence, so that G0 = p(β|µβ )p(φ|µφ )p(θ|µθ )p(η|µη )p(γ|µγ ).
Here, the µ terms represent hyperparameters. In this setting, the prior distribution factors so that in
line 6, for example, G0 (ω) ∝ p(β|µβ ). Furthermore, we could choose p(β|µβ ) to be a multivariate
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Gaussian with hyper mean vector and covariance matrix µβ = (λ, Σ). This allows us to performing
the sampling in line 6 using conjugacy. The idea is the same for the covariate model update in line
8 - where we could specify independent beta priors for binary variables, normal priors for continuous covariates, and Dirichlet priors for categorical variables. More complicated distributions can
be chosen to better model correlations between the parameters at the expense of computational
complexity.
Since there are no conjugate priors for the logistic models, the updates in lines 9 and 10 are done
(t−1)

using a Metropolis step. We use a multivariate normal jumping distribution centered around ηk
(t−1)

and γk

, respectively. The cluster assignment update beginning in line 13 is the most time-

consuming part of the algorithm as it requires updating each subject one at a time. Nevertheless, it
is simple to implement with existing statistical software.
At each iteration of the sampler, clusters can die (become unoccupied). New clusters can also
appear. If the proposed cluster’s parameters in line 12 happens to fit a subject’s data better than
the existing clusters, then the probability in line 15 will dominate those in line 14.
We compute n × n adjacency matrix, M (t) , for each posterior draw, t = 1, . . . , T . The (i, j)th entry,
(t)

(t)

Mij = I(ci

(t)

= cj ), of this matrix is an indicator for whether subject i was clustered with subject

j. Taking the element-wise mean of this matrix over Gibbs iterations, t, yields an n × n posterior
mode matrix, M ∗ displaying the frequency with which subject i was clustered with subject j.
To obtain a hard classification status for each patient, we search for the M (t) that is closest to
the posterior mode matrix, M ∗ , in the L2 sense. That is, we search for the posterior M (t) that
P
(t)
∗ 2
yield the lowest i,j (Mij − Mij
) . This approach provides an unambiguous way of classifying
subjects according to the posterior mode in the presence of label switching. The clusters can then
be summarized in terms of their outcome and observed confounder distributions.
Moreover, we can view M ∗ as a posterior adjacency matrix, represented as a network diagram
where each subject is represented by a node and the edge between subject i and j has length
∗
given by Mij
- the posterior probability of subject i and j being clustered together.

We alluded to the computational complexity of the algorithm earlier. In our data analysis, running
40,000 iterations (after 20,000 burn-in) with about 1,000 subjects and six covariates took about 3.3
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hours on a standard Windows 64-bit machine with 16GB of RAM, which we found to be reasonable.
In settings with larger sample sizes, several MCMC chains can be run in parallel. For example, four
chains that each take 10,000 draws after a 20,000 burn-in will yield a total of 40,000 draws in much
less time. If gains from parallelization is still insufficient, other algorithms for sampling from DP
posteriors exist that may potentially scale better with sample size. For example, the split-merge
algorithm (Jain and Neal, 2004) explores the posterior space of cluster assignments by proposing
splits and merges of existing clusters, instead of clustering one subject at a time.
Finally, we end with some guidance on choosing the initial number of clusters in the model. It is
advisable to conduct a few MCMC runs with different amounts of initial clusters and monitor some
posterior quantity of interest in each run. For example, we could choose to monitor marginal causal
effect chains for different numbers of starting clusters. The chains can be visually inspected to
make sure they mix well. A Gelman-Rubin R̂ statistic could be computed - with R̂ < 1.1 indicating
adequate mixing.

A.3. Causal Identification Assumptions
h
i
We can identify E YiAi =1 − YiAi =0 under these assumptions:
• Ignorability: YiAi =a ⊥ Ai = a|Li . Conditional on observed confounders, potential cost is
independent of treatment assignment. Unmeasured confounding, for example, would be a
violation of this assumption.
• Consistency: YiAi =a = Yi |Ai = a. That is, Yi observed under the actual treatment Ai = a
is equal to YiAi =a . Non-adherence to treatment assignment is an example of a violation of
consistency.
• No interference: YiAi =a ⊥ Aj , ∀i 6= j. one subject’s treatment assignment does not impact
another’s potential outcome. This assumption may not hold in vaccine studies, for example,
where one subject’s vaccination status may impact another subject’s infection status.
• Positivity: 0 < P (Ai = 1|Li ) < 1. If P (Ai = 1|Li ) = 1, then there would be some subpopulation, in terms of L, for which we would not have any control subjects to compare against.
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A.4. Simulation Details
We simulate 1000 data sets of 3000 subjects each under two data generating processes: a clustered setting and parametric setting. For the clustered setting, we simulate i ∈ 1, . . . , 3000 subjects
in the following way:
• Draw cluster indicators, ci with uniform probability P (ci = 1) = P (ci = 2) = P (ci = 3) = 1/3.
• Draw confounder vector Li ∼ P (Li |θci ) = N (L1 |µci , φci )

Q5

j=2

Ber(Lj |pci ). Where θci =

(µci , φci , pci ) and the cluster-specific parameters are θ1 = (.9, .12 , .25), θ2 = (0, .12 , .5), and
θ3 = (.375, .12 , .75).
• Draw treatment Ai |Li ∼ Ber(pci ), where p1 = expit(.5 − 1L1 +
P4
P4
2L1 − 2 j=2 Lj ), and p3 = expit(.8 + 1L1 − j=2 Lj ).

P4

j=2

Lj ), p2 = expit(.2 +

• Draw structural zero indicator, Zi |Ai , Li ∼ Ber(pzci ), where pz1 = expit(−2 − 2Ai + L1 +
P4
P4
P4
j=2 Lj ), pz2 = expit(−2+.5Ai −2L1 +2
j=2 Lj ), and pz3 = expit(2.5+1Ai −L1 −
j=2 Lj ).
• If Zi = 1, then set Yi = 0. Otherwise, draw Yi ∼ Gamma(shapeci , scaleci ) where scale1 =
10000, scale2 = 20000, and scale3 = 30000. The shape parameters are shape1 = 4 + A +
P4
P4
P4
2L1 + j=2 Lj , shape2 = 5 + A − 5L1 + j=2 Lj , and shape3 = 7 + A + 1L1 + j=2 Lj
For the parametric setting,
• Draw confounder vector Li ∼ P (Li |θ) = N (L1 |µ, φ)

Q5

j=2

Ber(Lj |p). Where θ = (µ, φ, p) =

(0, .12 , .5).
• Draw treatment Ai |Li ∼ Ber(p), where p = expit(2 + 3L1 −

P4

j=2

Lj ).

• Draw structural zero indicator, Zi |Ai , Li ∼ Ber(pz), where pz = expit(−2 + .5Ai − 2L1 +
P4
j=2 Lj ).
• If Zi = 1, then set Yi = 0. Otherwise, draw Yi ∼ Gamma(shape, scale) where scale = µ/1e9,
P4
shape = µ2 /1e9, and µ = 3e5 + 50000A − 100000L1 + j=2 Lj .
We implement BART using the BayesTree package, the doubly robust estimator using the twang
package, and code the Gamma hurdle and Gamma +.01 models in Stan with improper, uniform
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priors for all parameters. All Bayesian results are based on 5000 posterior draws after 5000 burn-in
iteration.
In both DGPs, for the DP mixture model, we use the base distribution, G0 , is the product of the
following priors:
• A Gaussian prior on L1 with mean equal to the empirical mean and variance equal to the
empirical variance scaled by 10. Independent Beta(1, 1) priors on L2:4 .
• A Gaussian prior on the coefficient vector of the non-zero outcome model (β). The mean of
this prior is centered around coefficient estimates from a linear model estimated using nonzero outcome values. The prior covariance matrix was set to be diagonal with variances equal
to variances from a linear model estimated using non-zero outcomes.
• An InvGamma(5, 10000) parameter is specified for the variance of the non-zero outcomes.
• The coefficient vectors of the logistic regression for both structural zeros and treatment were
assigned a Gaussian priors with a zero mean vector and variances set to 2. This is relatively
flat on the odds ratio scale.
• Both of the logistic regression parameter vectors were sampling using a Metropolis step with
a Gaussian jumping distributions with diagonal covariance matrices. The diagonal elements
were set to .05 for the treatment model and .005 for the structural zero model.

A.5. Data Analysis Details
We take 40,000 posterior draws after allowing for 20,000 burn-in. We initialize the sampler with
5 clusters. Normal priors on continuous covariate distributions. A Normal hyperprior is placed on
the mean of this prior with empirical means and standard deviations (scaled by 10 to be slightly
wider). Informative InvGam(10, 10) hyperprior placed on the variance. Beta(1, 1) priors are placed
on binary covariates distributions.
A Multivariate normal prior is placed on the outcome regression coefficients. The mean is set to
linear regression coefficient estimates using only subjects with positive costs. The prior covariance
was set to be diagonal with variance set to the diagonal of the previously mentioned regression’s
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covariance matrix. We scale these variances by 100 to make the prior a little wider. Treatment
model and zero-inflation model regresion parameters are also Gaussian, centered around zero
with variance of 2. Note that on an odds ratio scale this places most prior density on regression
odds ratios ranging from .014 to 70.
Multivariate normal jumping distributions with diagonal variances are used for the Metropolis steps
in both the treatment and zero-inflation models. The variance for the jumping distribution was set to
.025. Lastly, we choose to estimate the concentration parameter rather than setting it. We place an
InvGam(1, 1) prior on the parameter and implement a metropolis step using a Gaussian jumping
distribution with variance 1.
For standardization, we evaluated the necessary integrals with 30,000 Monte Carlo iterations per
posterior draw. The resulting MCMC chains are given

Figure A.1: Chains of 40,000 post-burn-in posterior draws of relevant quantities presented in the
data analysis section.
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Table A.1: Summary Statistics by Posterior Mode Cluster Assignment: Means are reported for
continuous variables. Percentages are reported for categorical variables. All monetary amounts
are in thousands of 2018 U.S. Dollars. Columns are ordered from lowest average cost to highest
average cost. Small clusters were omitted for compactness.
Red

Green

Blue

Orange

(n=452)

(n=160)

(n=288)

(n=127)

9.4

10.6

24

71.1

91.8%

93.1%

89.9%

89.8%

Age (years)

72.4

73.2

73.9

74.9

Household Income ($)

74.6

69.9

68.4

64.5

White

90.5%

88.8%

82.6%

85.8%

Diabetic

0.0%

40%

38.2%

25%

0

100%

15.0%

23.6%

22.0%

1

0.0%

85.0%

35.1%

31.5%

2

0.0%

0.0%

29.5%

15.7%

≥3

0.0%

0.0%

11.7%

30.7%

Grade = 1

21.7%

25%

21.2%

26.8%

FIGO Stage I-N0 or I-A

40.3%

39.4%

38.9%

42.5%

Total Inpatient Costs ($)
Radiation

CCI

A.6. Zero-Inflated DP Mixture with Log-Transformed Outcome
For applications with non-negative outcomes close to zero, a local Gaussian conditional outcome
distribution will likely yield negative predicted values. In these settings it may be desirable to have a
predictive distribution with non-negative support. In this section, we outline a simple modification to
our model to accommodate such scenarios. This involves log-transforming non-zero outcome values, then applying our model to the transformed data. This is equivalent to assuming a log-Normal
conditional distribution for non-zero outcomes, as opposed to a Normal distribution.

At the prediction step, we can exponentiate log-outcomes back to the original scale. Since we use a
fully Bayesian model, all inference is conducted using the posterior so that inference on the original
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scale is still probabilistically valid. Specifically, define a transformed outcome

Ẏi =




0

Yi = 0



log(Yi ) Yi > 0
We can now use the proposed zero-inflated conditional outcome distribution with this transformed
outcome
Ẏi | Ai , Li , βi , γi , φi ∼ π (x0i γi ) δ0 (ẏi ) + (1 − π (x0i γi )) · N (ẏi | x0i βi , φi )

We will illustrate this with a toy simulation example. We simulate a zero-inflated outcome, Yi , with
a single covariate, Xi , and no treatment for n = 600 subjects. Subjects are generated from three
unobserved, latent clusters ci ∈ {1, 2, 3} in the following way

p(ci = k) =

1
, for k ∈ {1, 2, 3}
3

Xi ∼ N (µ(ci ) , σ (ci ) )
(c )

(c )

Zi |Xi ∼ Ber(expit(γ0 i + γ1 i Xi ))



0
Zi = 1
Yi |Xi , Zi ∼


log N (β0(ci ) + β0(ci ) Xi , τ (ci ) ) Zi = 0

The true values are
• For ci = 1: β0 = 4, β1 = 1/10, γ0 = −.5, γ1 = −.5, µ = 10, τ = 1, σ = 3.
• For ci = 2: β0 = 5, β1 = 1/5, γ0 = −1, γ1 = .05, µ = 0, τ = 1, σ = 2.
• For ci = 3: β0 = 3, β1 = 1/10, γ0 = −2, γ1 = −.2, µ = −10, τ = 1, σ = 4.
We compute the transformed outcome Ẏi as defined above. Below is a figure of the data on both
the original and log scale. Notice the outcome values near zero ( Y < 500), the zero-inflation,
skew-ness, and multimodality - the pathological features our model aims to capture. We will show
that running our proposed model with the transformed outcome, Ẏ , will capture these complexities
on the original scale.
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Figure A.2: Simulated data on both original and log-scale.

We run our model with the transformed outcome, omitting the treatment model since in this toy
example we have no treatment.

Ẏi | Xi ∼ π(γ0i + γ1i Xi )δ0 (ẏi ) + (1 − π(γ0i + γ0i Xi )N (ẏ | β0i + β1i Xi , τi )
Xi ∼ N (xi |µi , σi )
ωi |G ∼ G
G|G0 , α ∼ DP (αG0 )

Above, ωi = (γ0i , γ1i , β0i , β1i , µi , σi , τi ). We set G0 to be the product of the following prior distributions (subscript i omitted for clarity):
• 2-dimensional Gaussian distribution for (β0 , β1 ) centered around OLS parameter estimates
using only positive outcomes. The prior covariance is the estimated covariance matrix from
this OLS regression.
• 2-dimensional Gaussian distribution for (γ0 , γ1 ) centered around the zero-vector with a diag-
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onal covariance diag(1, 1).
• Gaussian distribution for µ centered around the sample mean X̄ with variance equal to sample
P
variance Sx = (n − 1)−1 i (Xi − X̄)2
• InvGam(shape = 2, rate = Sx ) prior for σ.
• InvGam(2, 1) prior for τ .
• Gamma(1, 1) prior on α.
We initialize the model with 5 clusters and retain 1000 posterior draws after a 2000 draw burnin. Below is a figure depicting clustering and prediction results. In column 1, shapes indicated
posterior mode cluster assignment on both the original and log scale. In column 2, the observed
data distribution is shown with the 2D-density contours. A single predictive outcome draw for each
subject is depicted with the points. Note that the predictive draws are distributed similarly to the
contours - indicating a good fit on both the log and original scales.
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Figure A.3: Prediction and clustering results on original and log scales.

Below is a QQ plot similar to the one presented in the manuscript.
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Figure A.4: Percentiles of predictive draws versus observed percentiles, on original scale.

This shows that the posterior predictions on the original scale of the data faithfully represent the
data used for training - indicating a good fit despite being trained on the log-scale.
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APPENDIX B
A PPENDICES

FOR

C HAPTER 3

B.1. Identification of Causal Net Monetary Benefit
Recall that we are interested in estimating Ψ = E[M V 1,0 ] − E[M V 0,0 ], where the expectation
implicitly conditional on the parameters governing the joint cost-survival distribution. We can identify
each term of Ψ. Starting with an iterated expectation over L,

E[M V a,0 ] = EL [EY,D [M V a,0 | L, ω1:n , θ1:n , λ0 ]]
= EL [EY,D [M V a,0 |, A = a, δ = 0, L, ω1:n , θ1:n , λ0 ]]
= EL [EY,D [M V | A = a, δ = 0, L, ω1:n , θ1:n , λ0 ]]
Z
=
EY,D [M V | A = a, δ = 0, L, ω1:n , θ1:n , λ0 ]dP (L)
ZL Z
=
(Dκ − Y )p(Y, T | A = a, L, δ = 0, ω1:n , θ1:n , λ0 )dP (L)
L

Y,D

Note above, Y and D are the spaces we integrate over. This last line is each term of Equation
(3.3). The second line follows from joint ignorability (IA.1), allowing us to condition on A = a, δ = 0
after first conditioning on L. The third line follows from joint consistency, IA.2, allowing us to drop
the superscripts on monetary value. These are extensions of the usual conditional ignorability and
consistency assumptions under censoring (Robins, Hernán, and Brumback, 2000) extended to
handle a bivariate cost-survival time outcome. The interference assumption, IA.4, allows us to write
M V a1:n ,01:n = M V a,0 . That is, each subject’s potential monetary value is independent of others’
treatments or censoring status. Said another we, we learn nothing about someone else’s potential
monetary value by learning another’s treatment assignment. Joint positivity, IA.3, is requires so
that we do not condition on a zero-probability event in the second equality. The expression above
identifies a causal estimand that is purely a function of unknown parameters. Thus a posterior
distribution over the parameters induces a posterior distribution over monetary value.
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B.2. Posterior Computation
Gamma Process Prior Specification
This appendix provides additional details for updating the baseline hazard model with a dependent
Gamma process prior (Nieto-Barajas and Walker, 2002). Much of this is a detailed overview of the
results established by Nieto-Barajas and others in their 2002 paper and outlined in documentation
of the BGPhazard R package. We provide an abbreviated presentation adapted to the context of
our joint model for the reader’s convenience.
Consider observing right-censored survival time data for i = 1, . . . , n subjects with survival time Ti
and death indicator δi . Consider a partition, {τv }v=1:V , of the time interval such that 0 < τ1 < τ2 <
· · · < τV where τV > maxi (Ti ). In a setting with fixed study end, τ , we could set τV = τ . In this
case we consider equally-spaced interval such that ∆v = τv − τv−1 for all v. A piecewise constant
hazard model can be defined as

λ0 (t) =

V
X

λ0v I(τv−1 < t ≤ τv )

v=1

If a priori the baseline hazard λ0 (t) ∼ GP (bλ∗0 , b, ξ = 0), then the hazard rate in each interval follows λ0v ∼ Gam(bλ∗0v , b), where the first argument in the shape and the second argument is the
rate. In the shape, we’ve defined λ∗0v = {Λ∗0 (τv ) − Λ∗0 (τv−1 )}/∆v , where Λ∗0 denotes the prior cumulative hazard. Thus the prior mean hazard at each interval is E[λ0v ] = λ∗0v . This is known as the
independent Gamma process prior because the hazard at each increment is independent a priori.
The dependent Gamma process of Nieto-Barajas extends this process to introduce dependence
between hazards in nearby increments - providing a smoother estimate that is less dependent on
choice of time partition. They do this by introducing latent processes {cv }1:V and {uv }1:V and is denoted with GP, as above, but with ξ > 0. The process is initialized with λ1 ∼ Gam(bλ∗01 , b). Now for
v ∈ {1, 2, . . . τ − 1}, we have uv | λv , cv ∼ P ois(cv λ0v ) and λ0v+1 | uv , cv ∼ Gam(bλ∗0v+1 + uv , b+ cv ).
The conditional prior mean of this process is

E[λ0v | λ0v−1 ] =

bλ∗0v + cv−1 λ∗0v−1
b + cv−1

So the prior mean baseline hazard rate in current interval v is a weighted average of the prior
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baseline hazard rate, λ∗0v , in the current time interval and the prior baseline hazard rate in the
previous time interval, λ∗0v−1 . This is the induced AR(1) smoothness of the dependent Gamma
iid

Process. Following, Nieto-Barajas we place a hyperprior on {cv }1:V , assuming cv | ξ ∼ Exp(ξ).
Where the prior mean is E[cv ] = ξ. The magnitude of ξ (relative to b) controls the aggressiveness
of the prior AR(1) shrinkage. if ξ >> b, then on average cv−1 >> b at all intervals v, meaning
that E[λ0v | λ0v−1 ] ≈ λ∗0v−1 . Similarly, if ξ << b, then E[λ0v | λ0v−1 ] ≈ λ0v - i.e. almost no
shrinkage to the previous hazard. It can be shown above that setting ξ = 0 above reduces this to
the independent Gamma process.
Thus, the notation λ0 ∼ GP (bλ∗0 , b, ξ) denotes this prior for the piecewise constant model λ0 (t).
Specifically, the joint prior is
p(λ01:V , c1:V , u1:V | b, ξ) = p(λ1 )p(u1 | λ01 , c1 )

V
Y

p(uv | λv , cv )p(λ0v | uv−1 , cv−1 )

v=2

V
Y

p(cv | ξ)

(B.1)

v=1

With hyperparameters b, ξ, and λ∗0 . Notational dependence on λ∗0 has been suppressed for compactness. This can be combined with the likelihood for the observed data to obtain conditional
posteriors for each of the three parameter blocks, λ01:V , c1:V , and u1:V . We discuss likelihood
construction in the next section. b
Gamma Process Likelihood Construction
Now we consider the GP (bλ∗0 , b, ξ) prior for the baseline hazard in a proportional hazard model

PV
λ(t | Xi , θi ) = λ0 (t) exp Xi0 θi , where λ0 (t) = v=1 λ0v I(τv−1 < t ≤ τv ) . Specifically, our goal is
to find the posterior p({λ0v }1:V , {cv }1:V , {uv }1:V | D), where D indicates the observed data.
For convenience in presentation, define ηi = Xi0 θi . Also note that under the piece-wise constant
Rt
PV
model, the cumulative hazard is Λi (t) = 0 λ0 (s)eηi ds = v=1 λ0v eηi ∆v (t). Here, ∆v (t) = (t −
τv−1 )I(t ∈ (τv−1 , τv ]) + ∆v I(t > τv ).
Conditional on θi , standard survival likelihood construction with right-censored data yields
p(Ti | Xi , θi , δi , λ01:V ) =

Y

f (Ti | Xi , θi )

i|δi =1

Y

S(Ti | Xi , θi )

i|δi =1

Subjects with an event contribute to the likelihood via the density, f , and censored subjects contributed via the survival function S, both of which can be expressed in terms of the hazard. Denote
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λ0vi as the hazard rate of the increment in which subject i died. The density evaluated at subject
i’s death time is,

f (Ti | Xi , ηi ) = λ0 (Ti )e−Λi (Ti ) = λvi eηi exp

n

−

V
X

λ0v eηi ∆v (Ti )

o

(B.2)

v=1

The survival function in terms fo the hazard is,

S(Ti | Xi , θi ) = exp

n

V
o
n X
o
− Λi (Ti ) = exp −
λ0v eηi ∆v (Ti )
v=1

So the full likelihood is

p(Ti | Xi , θi , δi , λ01:V ) =

 Y

V
n

n X o
n X
X
o
λ0vi exp
ηi exp −
λ0v
eηi ∆v (Ti )

i|δi =1

i|δi =1

v=1

(B.3)

i=1

Gamma Process Posterior Updates
The likelihood (B.3) can be combined with the joint prior (B.1) to obtain the following conditional
posteriors distributions for u1:V , c1:V , and λ01:V . Note all of these distributions are also conditional
on data, D. First, the conditional posterior distribution of {cv }1:V is

p(cv | uv , λov+1 , λ0v ) ∝


n


cuv exp − (λ
v

0v

o
∗
+ λ0v+1 + 1ξ )cv (b + cv )λ0v+1 +uv



Gam(uv + 1, λ0v + 1 )
ξ

v = 1, . . . , V − 1
v=V
(B.4)

For v = 1, . . . , V − 1 this update is not conjugate. We sample each cv separately using Adaptive Metropolis-Hastings with separate proposal variances for each cv . The proposal variances
are tuned every few iterations in the burn-in period to target a 23.4% acceptance rate, which has
been shown to be optimal in around 10-dimensional sampling problems (roberts2001). The latent
process {uv }1:V can be updated from the following conditional posterior,

p(uv | cv , λ0v+1 , λ0v ) ∝


uv

 cv λ0v λ0v+1 (b+cv )


v = 1, . . . , V − 1



P ois(cv λ0v )

v=V

Γ(uv +1)Γ(λ∗
0v+1 +uv )
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(B.5)

Note here uv is integer-valued and non-conjugate for v = 1, . . . , V − 1. To sample from these
conditional posteriors, we use grid sampling with a large grid of points {0, . . . , 10000}. Finally, the
conditional posteriors of the hazard rate in each interval is given by

p(λ0v | −, D) =




P

Gam d1 + u1 + λ∗01 , c1 + b + ni=1 eηi ∆1 (Ti )

v=1



P

Gam dv + uv + uv−1 + λ∗0v , b + cv + cv−1 + ni=1 eηi ∆v (Ti )

v = 2, . . . , V
(B.6)

Above, dv is the number of deaths in interval v. Note that the conditional distribution is fully conjugate for all v and can be sampled directly. Note also that this update is the only Gamma Process
update that involves data. The processes u1:V and c1:V are latent and the updates do not involve
data - but they do induce a dependence between the λ0 v, which now must be updated sequentially
and in order.
Concentration Parameters
The two concentration parameters of the EDP, αθ and αω , are given Gam(1, 1) priors. We follow
the implementation in Roy et al., 2018. Details can be found in the supplement to their 2018 paper.
Monte Carlo Integration for Monetary Value
The expectation can be expressed as
Z

τ

Z

∞

µ(a, 0) = κE[D | −] −

E[Y | D, −]p(D | −)dY dD
0

0

Note we use “−” to denote the conditioning set, which was made explicit in the main body of the
paper.
• The first term, E[D | −], (average death time within 2-years under treatment a) can be computed in closed form. Since we partition time interval (see Appendix B.2) into K intervals, the
probability of dying in interval k is p(t ∈ [τk , τk + 1] | −). Within each interval, death time is
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uniform - so mean is

τk+1 +τk
.
2

E[D | −] ≈

K
X
τk+1 + τk
k=1

2

· p(t ∈ [τk , τk + 1] | −)

At every iteration, p(t ∈ [τk , τk + 1] | −) is given by substituting the parameter draws in this
iteration into Equation (B.2).
• Second term: For each subject, draw death interval proportional to p(t ∈ [τk , τk + 1] | −).
Then, within each interval draw a death time t∗ uniformly within that interval. Compute E[Y |
T = t∗ , −] using this drawn value and the parameter draws in the current iteration.

B.3. Simulation Details
Data Generation
In the log-normal setting, we simulate data as follows. For subject i = 1, . . . , N ,
• Simulate latent cluster membership: ci ∼ Ber(pc ), a 5-dimensional confounder Li . This
vector contains one continuous confounder drawn from a standard Normal distribution in the
first entry and four binary confounders draw from Bernoulli distribution with probability .5.
• Simulate treatment:
Ai ∼ Ber(expit(0 + (.1, .5, −.5, .5, −5)0 Li ))

• Simulate survival time, Ti : from a Weibull distribution (using the proportional hazard parameterization) with shape 10 and scale exp(ηi ). Where
ηi = ci · [(0, .1, −.1, .1, −.1)0 Li ] + (1 − ci ) · [(1, −.1, .1, −.1, .1)]) + (−3 + 2ci )Ai

Notice that the treatment effect on survival is bimodal, along with the covariate effects.
• Simulate a covariate-dependent censoring time: Ci , from the same Weibull as above.
• Simulate Observed time observed time: Draw Zi ∼ U nif (0, 1) and simulate censoring indicator δ̄i = I(Ci < Di ) · I(Zi < pδ ). If δ̄i = 1, then Ti = min(Ci , Di ).
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• Simulate accumulated cost up to Ti :


Yi ∼ log N mean = µi , sd = .05

where
µi = 2ci + (.1, .2, .2, .2, .2)0 Li − 2Ti + .3Ai
Here we have a bimodal cost distribution (different means depending on ci ) but homogeneous
treatment effect on costs.
• Output observed data Di = (Yi , Ti , δi = 1 − δ̄i , Li , Ai ).
In the Normal setting, we simulate data as above with the following modifications:
• Simulate survival and censoring times time with log scale parameter

ηi = ci · [(−1, .1, −.1, .1, −.1)0 Li ] + (1 − ci ) · [(1, −.1, .1, −.1, .1)]) + 2ci · Ai

Note again that treatment and covaraite effects are bimodal (dependent on ci ).
• Simulate outcome data from a Normal distribution with standard deviation .5 and mean

µi = 5 + 5ci + (.1, .5, .5, .5, .5)0 Li − 3Ai + Ti

• Here the treatment and covariate effects on Y are homogeneous.
We simulate each dataset with N = 1500. In the bimodal setting, pc = .5. In the parametric
setting, the pc = 0 - so all subjects are from the same cluster. We set pδ = .4 in the high setting
to target 20% censoring and pδ = .1 in the low setting to target 5% censoring. For each setting
Normal/log-Normal -pδ -pc combination, we simulate 200 such datasets.
EDP-GP Prior Settings
First we discuss the settings for the log-Normal data generating mechanism. For the Gamma
Process prior, we partition the interval from [0, max(Ti )] into equal size increments of .1. We set
ξ = 1e − 6 to be quite small (very flat) to allow the likelihood to drive the posterior estimate. We set
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b = ξ thus inducing an AR1 dependence between increments that is as informative as the shrinkage
towards λ∗0 , which we set to an exponential hazard with rate 400 - close to the average empirical
hazard rate across time points. Notice the actual baseline hazard is generated from a Weibull, so
our prior is deliberately misspecified as it likely would be in practice.
The prior on θi , G0θ is set to a multivariate Gaussian with zero mean vector and diagonal covariance
32 I6 . Where I6 is the 6 × 6 identity matrix, where 6 is the number of covariates (5 confounders and
one treatment indicator). This is flat on the hazard ratio scale.
Since we fit a Gaussian conditional model for Y , the prior G0ω is a product of a prior on the covariate
effects and prior on the variance. Regarding the former, we again use a multivariate Gaussian with
zero mean vector and covariance 32 I7 , where the identity matrix has a diagonal entry for the five
confounders, treatment indicator, and observed time. This is fairly flat relative to the true conditional
outcome variance (on log scale) of .052 . The prior for the variance is set to an inverse gamma
distribution. In the bi-modal setting we set this distribution to have shape and scale equal to 20.
This centers the prior variance around 1. In the parametric/unimodal setting we use a slightly
tighter prior around 1 - with shape and rate equal to 100. These tighter settings like 20 and 100
help regularize the Gaussian model we fit to the skewed Y data.
For the Normal data generating mechanism much of the settings above is the same. We only
change the shape parameter of the inverse gamma distribution on the conditional cost variance to
be 5 with a rate of 20. This is a fairly flat prior.
For each data set, we run the MCMC sampler for 7000 iterations and discard the first 2000 as
burn-in. This yields 5,000 posterior draws which we use for inference about NMB. In all settings, we
initialize the model with three ω clusters, each having three θ sub-clusters. This initialization is very
different from the true data generating mechanism that either generates data from a single ω − θ
cluster and two ω (top-level) clusters.
Since we fit a Gaussian model, each cluster’s conditional ω posterior is conjugate with our NormalInverse-Gamma prior. This is a simple update. For the θ cluster parameters we use a Metropolis
update with Gaussian jumping distribution. The jumping covariance is identity with .1 along the
diagonals. Similarly, we use a Metropolis step to update {c1:v }1:V (see Appendix B.2) at each step.
Each cv is updated from an independent Gaussian jumping distribution with variance .5. We adapt
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both of these jumping distribution variances every 25 iterations starting from iteration 50 and ending
at iteration 200 to target an acceptance rate of 23.4% per roberts2001
Doubly-Robust Implementation
Here we describe the doubly-robust NMB estimator of Li et al., 2018 implemented in our simulations. The cost and survival time models are estimated using super learner with regression trees,
generalized additive models, generalized linear models, and GLM-Net included in the ensemble.
We use a correctly specified logistic regression for the treatment model. This is quite generous
since doubly-robust estimators are guaranteed to be consistent with a correctly specified treatment
model (though the convergence rate can be quite slow if the outcome model is very misspecified.).
Since we have covariate dependent censoring, we estimate the inverse censoring weights using
a discrete-time failure model as described in Section 3.1.1 of their paper. To summarize, these
weights are computed using estimates of the probability of censoring at each time point, conditional
on not having been censored before that time point. This is estimated using a logistic regression of
a censoring indicator at each time point on simulated confounders, treatment and time-level fixed
effects. Intervals are computed using a 95% BCa interval after 1502 bootstrap iterations (BCa
intervals require more bootstrap iterations than observations in the sample).

B.4. Data Analysis Details
We partition the interval from [0, 24] into increments of .5. To sample from conditional posterior of
{cv }1:V (as mentioned Appendix B.2) we use a Metropolis-Hastings update from jumping variance
of .5. To sample from the posterior of θ (the covariate effects of the hazard model) we use a
joint Metropolis-Hastings update with an initial identity covariance matrix multiplied by .1 along
the diagonal. For both samplers, we adapt these jumping variances every 25 iterations starting
from iteration 50 to iteration 200. Every 25th iteration we use the previous 25 draws to target an
acceptance rate of 23.4%, as per roberts2001 Since we assume a log-normal cost distribution,
posterior updates are conjugate using log-transformed cost. Figure B.1 contains some diagnostic
plots with a discussion in the caption. These plots show the MCMC chains to be well-mixed and
model fit to be adequate. The total run-time was approximately 50 hours when parallelizing the
three chains.
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Figure B.1: Diagnostic plots supporting data analysis results. Top row: traceplots of three MCMC
chains of posterior NMB draws (left) and distribution of the combined posterior NMB draws of all
chains (right). These NMB draws are based on κ = $50, 000/12. All three chains mix after starting
with different initial clusters and seeds. Corresponding posterior is unimodal and peaked around
$14, 500. Panel C shows the traceplots of three MCMC chains for DSI, which mix well. Finally,
panel D shows a kernel density estimate of the joint observed time and cost distribution. In blue
we show a single set of posterior predictive draws of joint cost and observed time. This shows
adequate model fit: the posterior predictive is placing mass around the observed data. Moreover,
the posterior predictive allows for occasional large cost draws. This indicates the local log-Normal
cost distribution is able to capture skewness. If, for instance, the posterior predictive draws did not
overlap with the observed data, we would be suspicious of the model fit.
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For the doubly-robust (DR-SL) implementation of Li et al., 2018, we estimate the propensity score
model, cost model, and survival model using super learner with regression trees, GLM, and GLMnet
as candidates. Inverse censoring probability weights were estimated using a discrete-time failure
model described in Section 3.1.1 Li et al., 2018. This is a logistic model that predicts the probability
of censoring at each time point, conditional on not having been censored before that time point.
The discretization is at the monthly level, thus there are 24 intervals in which one can be censored
over τ = 24 months. The resulting model is used to predict the probability being censored at
the observed time, for each subject. The inverse of this probability is the weight used in the DR
approach. We include all Age, Household income, Charlson Index, and FIGO stage as covariates
in each model. Due to small cell counts, we combined FIGO stage II and II-NOS into a single
category. In the discrete-time failure model, we include a fixed effect for each month, 1-24. Due
to sparsity, we included month as a continuous covariate rather than categorical in this model.
In Figure B.2, displays NMB estimates from this DR-SL model in gray, along with the EDP-GP
estimates for reference. Note the larger uncertainty in the DR-SL model.
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Figure B.2: NMB mean and 95% bootstrap intervals for various willingness to pay from the DR-SL
model in gray. The EDP-GP estimates from Figure 3.3 are shown in blue for reference.
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APPENDIX C
A PPENDICES

FOR

C HAPTER 4

C.1. Identification of HTE
Here we identify the HTE in the point-treatment setting discussed in the paper. Recall the HTE is
the average treatment effect within stratum v, Ψ(v) = E[Y 1 | V = v] − E[Y 0 | V = v]. Consider the
term E[Y a | V = v] and now iterate expectation over W :
Z

a

E[Y | V = v] =

E[Y a | W, V = v]dPv (W )

W

Now we assume conditional ignorability. Specifically that within stratum v, once we condition on
confounders W , treatment assignment is independent of potential outcome, Y a ⊥ A | W, V = v.
This implies that E[Y a | W, V = v] = E[Y a | A = a, W, V = v],

E[Y a | V = v] =

Z

E[Y a | A = a, W, V = v]dPv (W )

W

Now, we assume consistency. That is, the outcome actually observed under treatment assignment
A = a actually equals the outcome that would occur under treatment A = a, i.e. Y a = Y . This
would be violated if, for instance, there is non-adherence to treatment assignment. This yields,

E[Y a | V = v] =

Z
E[Y | A = a, W, V = v]dPv (W )
W

So we have identified each term of Ψ(v) as a regression averaged over Pv (W ) = P (W | V = v).
Note that we implicitly make a positivity and non-adherence assumption. By conditioning on A = a
within W and V , we are assuming that treatment probability is bounded 0 < P (A = 1 | W, V =
v) < 1 or else we would be conditioning on a zero-probability even. This is also known as “overlap”.
Causally, it would suggest that there is some level and W within stratum V where we only observed
patients assigned to one of the two treatments. We cannot estimate a causal effect in this region of
the data without (likely incorrect) extrapolation. Moreover, for a particular sample we have assumed
that each subjects potential outcome Yiai is unaffected by others’ treatment assignment. If subject
j’s treatment assignment impacts subject i’s potential outcome, then we would have had to index
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ai ,aj

the potential outcome with this treatment as well, Yi

.

C.1.1. Posterior Derivations
Here we provide a derivation of the posterior distribution of each Pv using Dirichlet Distributions - the
finite-dimensional analogue of the Dirichlet Process. This is to supplement the conjugacy results
used in the main text. Suppose our model for the conditional covariate distribution, Pv (W ) = P (W |
V = v), is
Pv (W | π v ) =

n
X

πiv · δWi (W )

i=1

We have K such distributions for each of the K levels of V . Consider the Dirichlet prior on each
π v = (π1v , π2v , . . . , πnv ) conditional on the π = (π1 , π2 , . . . , πn ) and α mentioned in the text,
π v | π, α ∼ Dir(απ)

Note, we could do everything in terms of v-specific concentration parameters, but use a common α
for compactness. Now place Dirichlet hyperprior on π:

π | γ ∼ Dir(γ1n )

Note that the HBB corresponds to setting γ = 0 and that α is user-specified but we will leave γ as
it is for now. So the joint posterior is
Pn
n
K
nY
Γ( i=1 απi ) Y v απi +δv (Vi )−1 o
Qn
(πi )
p(π | γ)
p(π , π , . . . π , π | α, γ, W, V ) ∝
i=1 Γ(απi ) i=1
v=1
1

2

K

(C.1)

The objective is to sample the π v . To do this, we sample from the joint and simply ignore draws of
π. Note that the joint can be expressed as a marginal posterior for π and independent conditional
posteriors for π v

p(π 1 , π 2 , . . . π K , π | α, γ, W, V ) = {

K
Y

p(π v | π, α, γ, W, V )}p(π | α, γ, W, V )

v=1

Thus to sample from the joint, we first sample π from the marginal posterior. Then conditional on π,
we can sample the π v independently. These are exactly Step 1 and 2, respectively, in the algorithm
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of Section 4.3.1. We now derive this marginal posterior and then turn to the conditional posteriors
of π v . To get the marginal, integrate out each of the π v in (C.1)
Pn
n
Γ( i=1 απi ) Y v απi +δv (Vi )−1 v o
Qn
(πi )
dπ p(π | γ)
i=1 Γ(απi ) i=1
v=1 Πv
Qn
Qn
K
nY
o
Γ(α)
i∈Sv Γ(απi + 1)
i∈S
/ v Γ(απi )
Qn
∝
p(π | γ)
Γ(α + nv )
i=1 Γ(απi )
v=1

p(π | α, γ, W, V ) ∝

K Z
nY

Above, Πv is the n-dimensional simplex we integrate over. This result follows because the integral
is over the kernel of a Dirichlet distribution, with concentration parameter vector απi + δv (Vi ) and
Pn
recognizing that i=1 απi = α since πi sum to 1. Continuing the derivation, we cancel like terms
from the numerator and denominators and note that Γ(απi + 1) = απi Γ(απi ). Therefore,

Γ(απi +1)
Γ(απi )

=

απi and we have

p(π | α, γ, W, V ) ∝

n
K
nY
Γ(α)αnv o Y
( πi )p(π | γ)
Γ(α + nv ) i=1
v=1

Now, note that in the last line the term in brackets is constant with respect to π, so we can eliminate
Qn
it and maintain proportionality. Then, substituting the prior p(π | γ = 0) = Dir(0n ) ∝ i=1 πi−1 ,

p(π | α, γ, W, V ) ∝ (

n
Y

πi )

i=1

n
Y
i=1

πi−1 ∝

n
Y

πi1−1

i=1

This is the kernel of Dir(1n ) - the posterior of Rubin’s bootstrap. Thus, to draw from this marginal
posterior, we can draw π ∼ Dir(1n ). This is the distribution we sample from in Step 1 of the
algorithm in Section 4.3.1.
Now, the conditional posterior of each π v conditional on π is much simpler. Just absorb all terms
not involving πiv in (C.1) into the proportionality constant and we have
p(π v | π, α, γ, W, V ) ∝

n
Y

(πiv )απi +δv (Vi )−1

i=1



Which is proportional to a π v ∼ Dir απ1 + δv (V1 ), απ2 + δv (V2 ), . . . , απn + δv (Vn ) . This is the
distribution we sample from in Step 2 of the algorithm in Section 4.3.1.
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C.1.2. Simulation Details
Here we provide details for the simulation study in Section 4.4. In each setting, we simulate 1000
data sets with n = 300 subjects as follows. For i = 1, . . . , 300
1. Simulate stratum allocation:

Vi ∼ M ultinom(1;

4 3 2 1
, , , )
10 10 10 10

The parameter vectors gives the probability of assignment to stratum 1, 2, 3, and 4, respectively.
2. Simulate 10-dimensional confounder vector Wi = (Wip )p=1:10 ,

Wi | Vi = v ∼ p(W | V = v)

The form of p(W | V = v) varies with simulation setting and is specified below.
3. Simulate treatment assignment, Ai , from Bernoulli with probability
P (A = 1 | Wi , Vi = v) = expit(ηv + Wi0 β)

4. Simulate binary outcome, Yi , from a Bernoulli with probability
P (Y = 1 | Wi , Vi = v) = expit(−1 + γv + Wi0 θ + αv Ai )

Note in the above that Wi impacts both treatment assignment (via β) and outcome (via θ) - so it is
a confounder. Similarly, Vi impacts both treatment assignment (via ηv ) and outcome (via γv ). Note
that the conditional treatment effect, αv , varies across stratum - so this is a complex scenario with
treatment effect heterogeneity across strata. This yields a simulated data set {Yi , Ai , Wi , Vi }i=1:n .
We simulate 1000 such data sets across four settings.
The covariate distribution p(W | V ) has a different family governed by different parameters in each
of the four settings, 1 − 4:
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1. Wip ∼ N (0, 1) for all V = v.
2. Wip | V = v ∼ N (µv , 1) where µv ∈ {−2, 0, 2, 4} for v = 1, . . . 4, respecting order. Marginal of
V , the distribution of W is a location mixture of normals.
3. Wip | V = v ∼ Ber(pv ) where pv ∈ {.8, .6, .4, .2} for v = 1, . . . 4, respecting order.
4. Wip | V = v ∼ Gam(shape = 21 τv , rate = 12 ). Here τv ∈ {8, 6, 4, 1} for v = 1, . . . 4, respecting
order.
All settings share these simulation parameters:
• Set β = θ = (1, −1, 1, −1, 1, −1, 1, −1, 1, −1).
• Set ηv ∈ (0, −.5, .5, .5) for v = 1, . . . , 4 in order.
• γv ∈ (−.1, −.5, .1, .5) for v = 1, . . . , 4 in order.
• αv ∈ (1, −1.5, 1, 1.5) for v = 1, . . . , 4 in order.
Using each simulated dataset, we specify the following logistic regression


P (Y | A, W, V = v) = expit ω0 + ωv + W 0 ωW + ωv∗ A

Normal priors with mean zero and standard deviation 3 were placed on each parameter. We obtain
(m)

M = 5000 posterior samples {ω0 , ω1

(m)

, . . . , ω4

(m)

∗(m)

, ωW , ω1

∗(m)

, . . . , ω4

}m=1:M after discarding the

first 5000 draws as burn-in. Sampling was done via Hamiltonian Monte Carlo as implemented in
Stan. These samples were combined with HBB as described in Section 4.3.1.
C.1.3. Data Analysis Details
Here we provide additional details about the data analysis in the main text. In the parametric
Poisson model, we include the following covariates for each stratum except gynecological cancer.
• treatment: binary with one indicating proton.
• race: categorical with levels white, black, and other.
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• sex: binary with one indicating male.
• insurance: categorical with levels medicare, private, and other.
• body-mass index: normalized.
• age: normalized
• charlson index: logged.
For gynecological cancer, there is no need to adjust for sex. We specifyN (0, 1) priors on all covariates except in the following instances: in the models for E/G, brain, anal, and rectum, we use tighter
N (0, .1) priors on the other race coefficient. Similarly, for the P/D/H model we use a N (0, .1) prior
on other insurance. The tight priors are to regularize coefficients that explode due too little variation in insurance status or race in a particular stratum. Non-bayesian analyses typically omit such
variables (equivalent to a prior that the coefficient is exactly 0), but we choose to include them with
a tight prior around 0 as a compromise. Note that the N (0, 1) prior may seem overly informative,
but on the log scale it is quite flat. It puts sufficient volume at incident rate ratios within exp(±1.96)
or within (.14, 7.1).
For posterior sampling, we use hamiltonian monte carlo as implemented in Stan. We call Stan in
R using the rstan package. For inference, we retain 10000 posterior draws after a 10000 burn-in.
After obtaining these draws, we use HBB as described in Section 4.3.1.
For the BART model, we adjust for all of the same covariates. Draws of fv under particular treatments were obtained using the BayesTree R package. We retain 1000 posterior draws for inference after discarding the first 1000 as burn-in. For the BART hyperpriors, we increase the power
parameter from the default of 2 to 3. This is to favors more shallow trees which provides more
regularization. After draws of fv are obtained, we combine with HBB draws as described in Section
4.3.1.
Finally, we note that the effects in the gynecological cancer model, in particular, is highly variable.
As there were only 4 subjects treated with proton therapy in this stratum and none of the four had
events, this coefficient is not identifiable with data. This is manifest in the large interval in both the
Poisson and BART models.
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